Citation Report
List of articles citing

Ligand efficiency: a useful metric for lead selection

DOI: 10.1016/s1359-6446(04)03069-7
Drug Discovery Today, 2004, 9, 430-1.

#	Paper	IF	Citations
1593	Discovery and Biological Evaluation of Potent and Selective NMethylene Saccharin-Derived Inhibitors for Rhomboid Intramembrane Proteases.		
1592	CellFy: A Cell-Based Fragment Screen against CType Lectins.		
1591	Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors.		
1590	Discovery of Novel KRAS-PDE Inhibitors by Fragment-Based Drug Design.		
1589	Fragment-based lead discovery. **2004**, 3, 660-72		618
1588	Complex molecules: do they add value?. **2005**, 9, 310-6		55
1587	Fragonomics: fragment-based drug discovery. **2005**, 9, 366-70		102
1586	Improving success rates for lead generation using affinity binding technologies. **2005**, 16, 666-73		18
1585	A new school for screening. **2005**, 23, 184-6		16
1584	Ligand efficiency indices as guideposts for drug discovery. *Drug Discovery Today*, **2005**, 10, 464-9	8.8	463
1583	Structural biology and drug discovery. *Drug Discovery Today*, **2005**, 10, 895-907	8.8	261
1582	Widening bottlenecks in drug discovery: glimpses from Drug Discovery Technology Europe 2005. *Drug Discovery Today*, **2005**, 10, 820-2	8.8	3
1581	Fragment-based lead discovery: leads by design. *Drug Discovery Today*, **2005**, 10, 987-92	8.8	294
1580	Library design for fragment based screening. **2005**, 5, 751-62		176
1579	Fragment-based lead discovery using X-ray crystallography. *Journal of Medicinal Chemistry*, **2005**, 48, 403-13	8.3	379
1578	A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. *Journal of Medicinal Chemistry*, **2005**, 48, 1489-95	8.3	491
1577	Knowledge and Intelligence in Drug Design. **2006**, 425-437		6

1576	Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods. *Journal of Medicinal Chemistry*, **2006**, 49, 4992-5000	8.3	128
1575	Fragment screening: an introduction. **2006**, 2, 430-46		123
1574	Fragment screening by biochemical assay. **2006**, 1, 225-36		39
1573	Profiling of membrane proteins from human macrophages: comparison of two approaches. **2006**, 6, 2365-75		18
1572	Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 1346-55	8.3	121
1571	Chemical diversity and biological activity. **2006**, 3, 387-395		16
1570	In silico-guided target identification of a scaffold-focused library: 1,3,5-triazepan-2,6-diones as novel phospholipase A2 inhibitors. *Journal of Medicinal Chemistry*, **2006**, 49, 6768-78	8.3	62
1569	Relationships between Molecular Complexity, Biological Activity, and Structural Diversity. *Journal of Chemical Information and Modeling*, **2006**, 46, 525-35	6.1	78
1568	Concepts in receptor optimization: targeting the RGD peptide. **2006**, 128, 4675-84		36
1567	Exhaustive de novo design of low-molecular-weight fragments against the ATP-binding site of DNA-gyrase. *Journal of Chemical Information and Modeling*, **2006**, 46, 1168-73	6.1	15
1566	COSMOsim: bioisosteric similarity based on COSMO-RS sigma profiles. *Journal of Chemical Information and Modeling*, **2006**, 46, 1040-53	6.1	20
1565	Fragment-based drug design: how big is too big?. *Journal of Medicinal Chemistry*, **2006**, 49, 6972-6	8.3	246
1564	Probing molecular docking in a charged model binding site. **2006**, 357, 1449-70		50
1563	. **2006**,		56
1562	Design and Development of Signal Transduction Inhibitors for Cancer Treatment: Experience and Challenges with Kinase Targets. **2006**, 1, 13-23		30
1561	Global mapping of pharmacological space. **2006**, 24, 805-15		686
1560	Deconstructing fragment-based inhibitor discovery. **2006**, 2, 720-3		123
1559	New approaches to molecular cancer therapeutics. **2006**, 2, 689-700		307

1558	How good is your screening library?. **2006**, 10, 352-6		34
1557	Fragment-based lead discovery: a chemical update. **2006**, 17, 643-52		131
1556	Molecular modelling. **2006**, 2, 660-81		8
1555	Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. *Drug Discovery Today*, **2006**, 11, 175-80	8.8	138
1554	Computational chemistry-driven decision making in lead generation. *Drug Discovery Today*, **2006**, 11, 43-50	8.8	65
1553	Can we rationally design promiscuous drugs?. **2006**, 16, 127-36		421
1552	In silico ADMET traffic lights as a tool for the prioritization of HTS hits. **2006**, 1, 1229-36		87
1551	Pyramid: An Integrated Platform for Fragment-based Drug Discovery. **2006**, 193-214		10
1550	Fragment-based Lead Discovery and Optimization Using X-Ray Crystallography, Computational Chemistry, and High-throughput Organic Synthesis. **2006**, 215-248		26
1549	Entropic Consequences of Linking Ligands. **2006**, 55-66		11
1548	SAR by NMR: An Analysis of Potency Gains Realized Through Fragment-linking and Fragment-elaboration Strategies for Lead Generation. **2006**, 181-192		8
1547	Hot-spot mimicry of a cytokine receptor by a small molecule. **2006**, 103, 15422-7		119
1546	Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. **2006**, 361, 413-23		115
1545	Screening-based discovery and structural dissection of a novel family 18 chitinase inhibitor. **2006**, 281, 27278-85		42
1544	Structure-Based Drug Discovery. **2007**,		23
1543	Ligand efficiency indices for effective drug discovery. **2007**, 2, 469-88		211
1542	Structure-based calculation of drug efficiency indices. **2007**, 23, 2678-85		23
1541	Free resources to assist structure-based virtual ligand screening experiments. **2007**, 8, 381-411		91

1540	SPR-based fragment screening: advantages and applications. **2007**, 7, 1630-42		175
1539	Fragment-based drug discovery: what has it achieved so far?. **2007**, 7, 1544-67		62
1538	Design of second generation phosphodiesterase 5 inhibitors. **2007**, 7, 405-19		46
1537	New Applications for Structure-Based Drug Design. **2007**, 775-806		0
1536	Ligand configurational entropy and protein binding. **2007**, 104, 1534-9		308
1535	Lead Identification by Virtual Screening. 651-704		2
1534	Picking pockets to fuel antimicrobial drug discovery. **2007**, 35, 980-4		5
1533	Properties Guiding Drug- and Lead-Likeness. **2007**, 439-461		6
1532	Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. *Journal of Medicinal Chemistry*, **2007**, 50, 2289-92	8.3	55
1531	Chapter 28 Fragment-Based Lead Discovery. **2007**, 42, 431-448		19
1530	Highly efficient ligands for dihydrofolate reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural analysis. *Journal of Medicinal Chemistry*, **2007**, 50, 940-50	8.3	63
1529	Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of beta-secretase. *Journal of Medicinal Chemistry*, **2007**, 50, 1124-32	8.3	141
1528	On sampling of fragment space. *Journal of Medicinal Chemistry*, **2007**, 50, 3214-21	8.3	32
1527	Fragment-based drug discovery using the SHAPES method. **2007**, 2, 1555-66		13
1526	Application of fragment screening by X-ray crystallography to beta-secretase. *Journal of Medicinal Chemistry*, **2007**, 50, 1116-23	8.3	139
1525	An Introduction To Chemoinformatics. **2007**,		191
1524	The structural determinants of macrolide-actin binding: in silico insights. **2007**, 92, 3862-7		5
1523	Docking and Scoring for Structure-based Drug Design. 541-599		5

1522	Discovery of a novel warhead against beta-secretase through fragment-based lead generation. *Journal of Medicinal Chemistry*, **2007**, 50, 5903-11	8.3	139
1521	Identification of inhibitors of protein kinase B using fragment-based lead discovery. *Journal of Medicinal Chemistry*, **2007**, 50, 2293-6	8.3	120
1520	Polyfluorinated amino acids for sensitive 19F NMR-based screening and kinetic measurements. **2007**, 129, 5665-72		40
1519	Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. *Journal of Medicinal Chemistry*, **2007**, 50, 5912-25	8.3	197
1518	Docking and Scoring. **2007**, 255-281		
1517	Library Design: Ligand and Structure-Based Principles for Parallel and Combinatorial Libraries. **2007**, 307-336		1
1516	Chemogenomics in Drug Discovery The Druggable Genome and Target Class Properties. **2007**, 421-433		4
1515	Lead Discovery and the Concepts of Complexity and Lead-Likeness in the Evolution of Drug Candidates. **2007**, 435-458		
1514	Screening Library Selection and High-Throughput Screening Analysis/Triage. **2007**, 495-513		
1513	De Novo Design. **2007**, 283-305		6
1512	Fragment-Based Approaches. **2007**, 939-957		1
1511	. **2007**,		6
1510	High-throughput lead finding and optimisation for GPCR targets. **2006**, 249-67		3
1509	Nanomolar inhibition of type II dehydroquinase based on the enolate reaction mechanism. **2007**, 2, 101-12		23
1508	GPCR targeted library design: novel dopamine D3 receptor ligands. **2007**, 2, 1000-5		11
1507	Fragment docking to S100 proteins reveals a wide diversity of weak interaction sites. **2007**, 2, 1648-54		14
1506	Fragment-based approaches to enzyme inhibition. **2007**, 18, 489-96		88
1505	The role of molecular size in ligand efficiency. *Bioorganic and Medicinal Chemistry Letters*, **2007**, 17, 4258-61		130

1504	Fragment-based screening using X-ray crystallography and NMR spectroscopy. **2007**, 11, 485-93		137
1503	Application of mass spectrometry technologies for the discovery of low-molecular weight modulators of enzymes and protein-protein interactions. **2007**, 11, 511-7		29
1502	Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis. **2007**, 63, 1208-16		17
1501	Protein-protein recognition and interaction hot spots in an antigen-antibody complex: free energy decomposition identifies "efficient amino acids". **2007**, 67, 418-34		74
1500	Identification of novel fragment compounds targeted against the pY pocket of v-Src SH2 by computational and NMR screening and thermodynamic evaluation. **2007**, 67, 981-90		29
1499	A decade of fragment-based drug design: strategic advances and lessons learned. **2007**, 6, 211-9		841
1498	Scaffold selection and scaffold hopping in lead generation: a medicinal chemistry perspective. *Drug Discovery Today*, **2007**, 12, 149-55	8.8	119
1497	Optimizing fragment and scaffold docking by use of molecular interaction fingerprints. *Journal of Chemical Information and Modeling*, **2007**, 47, 195-207	6.1	302
1496	Chapter 16:Discovery and Extrapolation of Fragment Structures towards Drug Design. **2007**, 293-318		1
1495	Chapter 4:Application and Limitations of X-Ray Crystallographic Data in Structure-Guided Ligand and Drug Design. **2007**, 73-94		2
1494	Molecular Modelling. **2007**, 54-96		
1493	Structure Determination - Crystallography for Structure-Based Drug Discovery. **2007**, 32-53		1
1492	Fragment Screening: An Introduction. **2007**, 142-172		1
1491	The challenges of developing novel antiparasitic drugs. **2007**, 7, 245-50		26
1490	CONFIRM: connecting fragments found in receptor molecules. **2008**, 22, 761-72		23
1489	Structure-based tailoring of compound libraries for high-throughput screening: discovery of novel EphB4 kinase inhibitors. **2008**, 73, 11-8		56
1488	Group efficiency: a guideline for hits-to-leads chemistry. **2008**, 3, 1179-80		76
1487	Optimization of 5-aryloxyimidazole non-nucleoside reverse transcriptase inhibitors. **2008**, 3, 1756-62		13

1486	Novel inhibitors of anthrax edema factor. **2008**, 16, 7225-33		32
1485	Tyramine fragment binding to BACE-1. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 1304-7	2.9	58
1484	Synthesis and structure based optimization of novel Akt inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3359-63	2.9	56
1483	IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 3656-60	2.9	45
1482	4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinase. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4316-20	2.9	40
1481	Achieving multi-isoform PI3K inhibition in a series of substituted 3,4-dihydro-2H-benzo[1,4]oxazines. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4700-4	2.9	19
1480	Triazole oxytocin antagonists: identification of aryl ether replacements for a biaryl substituent. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5242-4	2.9	17
1479	Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5487-92	2.9	27
1478	Fragment-based activity space: smaller is better. **2008**, 12, 260-8		50
1477	The impact of natural products upon modern drug discovery. **2008**, 12, 306-17		421
1476	Blood-brain barrier permeability considerations for CNS-targeted compound library design. **2008**, 12, 318-23		75
1475	Structure-based dissection of the natural product cyclopentapeptide chitinase inhibitor argifin. **2008**, 15, 295-301		46
1474	Discovery of brain penetrant, soluble, pyrazole amide EP1 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4027-32	2.9	13
1473	Discovery of triazolinone non-nucleoside inhibitors of HIV reverse transcriptase. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4348-51	2.9	31
1472	Design and optimization of potent, selective antagonists of Oxytocin. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 4278-81	2.9	10
1471	Lead-Likeness and Drug-Likeness. **2008**, 244-254		7
1470	Computational chemistry approaches to drug discovery in signal transduction. **2008**, 3, 452-70		19
1469	Network pharmacology: the next paradigm in drug discovery. **2008**, 4, 682-90		2255

1468	Perspectives on NMR in drug discovery: a technique comes of age. **2008**, 7, 738-45		318
1467	Strategies and tactics for optimizing the Hit-to-Lead process and beyond--a computational chemistry perspective. *Drug Discovery Today*, **2008**, 13, 99-109	8.8	43
1466	Recent developments in fragment-based drug discovery. *Journal of Medicinal Chemistry*, **2008**, 51, 3661-80	8.3	525
1465	Fragment-based drug discovery using rational design. **2007**, 169-85		11
1464	Designing a Fragment Process to Fit Your Needs. 15-37		2
1463	A dominant conformational role for amino acid diversity in minimalist protein-protein interfaces. **2008**, 381, 407-18		65
1462	Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. *Journal of Medicinal Chemistry*, **2008**, 51, 2147-57	8.3	82
1461	Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. *Journal of Medicinal Chemistry*, **2008**, 51, 183-6	8.3	44
1460	Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase. *Journal of Medicinal Chemistry*, **2008**, 51, 3804-13	8.3	50
1459	Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. *Journal of Medicinal Chemistry*, **2008**, 51, 4986-99	8.3	267
1458	Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant. *Journal of Chemical Information and Modeling*, **2008**, 48, 2074-80	6.1	42
1457	Fragment-Based Drug Discovery. **2008**, 228-243		4
1456	The Role of Functional Groups in Drug–Receptor Interactions. **2008**, 464-480		7
1455	Protein Crystallography and Drug Discovery. **2008**, 605-634		1
1454	Fragment-based approach to drug lead discovery: overview and advances in various techniques. **2008**, 9, 217-27		45
1453	Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. *Journal of Medicinal Chemistry*, **2008**, 51, 2457-67	8.3	145
1452	Identification of MMP-12 inhibitors by using biosensor-based screening of a fragment library. *Journal of Medicinal Chemistry*, **2008**, 51, 3449-59	8.3	49
1451	Novel prostaglandin D synthase inhibitors generated by fragment-based drug design. *Journal of Medicinal Chemistry*, **2008**, 51, 2178-86	8.3	58

1450	Modern cancer drug discovery: integrating targets, technologies and treatments. **2008**, 3-38		3
1449	Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. **2008**, 130, 3900-14		88
1448	Differences between high- and low-affinity complexes of enzymes and nonenzymes. *Journal of Medicinal Chemistry*, **2008**, 51, 6432-41	8.3	23
1447	Statistical analysis of the effects of common chemical substituents on ligand potency. *Journal of Medicinal Chemistry*, **2008**, 51, 553-64	8.3	80
1446	AQP1 expression analysis in human diseases: implications for proteomic characterization. **2008**, 5, 29-43		12
1445	Label-free primary screening and affinity ranking of fragment libraries using parallel analysis of protein panels. **2008**, 13, 202-9		49
1444	Compound Properties and Drug Quality. **2008**, 481-490		3
1443	The Role of Functional Groups in Drug–Receptor Interactions. **2008**, 359-378		6
1442	Computational discovery of novel low micromolar human pregnane X receptor antagonists. **2008**, 74, 662-72		62
1441	Small-Molecule Inhibitors of Protein–Protein Interactions: Challenges and Prospects. **2008**, 199-233		2
1440	Assembling a Fragment Library. 39-62		4
1439	Practical Aspects of Using NMR in Fragment-Based Screening. 63-98		1
1438	Virtual Fragment Scanning: Current Trends, Applications and Web-Based Tools. 223-244		1
1437	. **2008**,		21
1436	Structural biology and anticancer drug design. **2008**, 91-106		1
1435	. **2009**,		19
1434	The Process of Drug Discovery. **2009**, 149-177		
1433	NMR Spectroscopy in Fragment Based Drug Design. **2009**, 125-139		1

1432	Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking. **2009**, 3, e356		60
1431	Molecular basis for Bcl-2 homology 3 domain recognition in the Bcl-2 protein family: identification of conserved hot spot interactions. **2009**, 284, 17499-511		20
1430	Integrating surface plasmon resonance biosensor-based interaction kinetic analyses into the lead discovery and optimization process. **2009**, 1, 1399-414		30
1429	Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway. **2009**, 1, 137-55		24
1428	Endothelin receptor antagonists: status and learning 20 years on. *Progress in Medicinal Chemistry*, **2009**, 47, 203-37	7.3	17
1427	Fragment library screening and lead characterization using SPR biosensors. **2009**, 9, 1725-35		64
1426	From fragment screening to potent binders: strategies for fragment-to-lead evolution. **2009**, 9, 956-61		12
1425	Computational fragment-based binding site identification by ligand competitive saturation. **2009**, 5, e1000435		161
1424	Hit Triage: Medicinal Chemistry Strategies to Improve the Odds of Success in Discovery. **2009**, 141-174		1
1423	Lead Identification. **2009**, 175-212		
1422	Dequalinium, a new inhibitor of Mycobacterium tuberculosis mycothiol ligase identified by high-throughput screening. **2009**, 14, 643-52		34
1421	Structure-based design of molecular cancer therapeutics. **2009**, 27, 315-28		57
1420	Dynamic template-assisted strategies in fragment-based drug discovery. **2009**, 27, 512-21		41
1419	Two 'Golden Ratio' indices in fragment-based drug discovery. *Drug Discovery Today*, **2009**, 14, 321-8	8.8	49
1418	Predicting druggable binding sites at the protein-protein interface. *Drug Discovery Today*, **2009**, 14, 155-61	6.8	230
1417	'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. *Drug Discovery Today*, **2009**, 14, 31-40	8.8	103
1416	Ligand efficiency and fragment-based drug discovery. *Drug Discovery Today*, **2009**, 14, 278-83	8.8	156
1415	Transforming fragments into candidates: small becomes big in medicinal chemistry. *Drug Discovery Today*, **2009**, 14, 630-46	8.8	161

1414	From fragment to clinical candidate--a historical perspective. *Drug Discovery Today*, **2009**, 14, 668-75	8.8	186
1413	NMR methods in fragment screening: theory and a comparison with other biophysical techniques. *Drug Discovery Today*, **2009**, 14, 1051-7	8.8	125
1412	Structural biology contributions to tyrosine kinase drug discovery. **2009**, 21, 280-7		46
1411	Structure-based pharmacophore screening for natural-product-derived PPARgamma agonists. **2009**, 10, 75-8		31
1410	Crystal structure analysis and in silico pKa calculations suggest strong pKa shifts of ligands as driving force for high-affinity binding to TGT. **2009**, 10, 716-27		21
1409	Thermodynamic optimisation in drug discovery: a case study using carbonic anhydrase inhibitors. **2009**, 4, 1985-9		58
1408	Organic dyes as small molecule protein-protein interaction inhibitors for the CD40-CD154 costimulatory interaction. **2010**, 23, 65-73		7
1407	Library screening by fragment-based docking. **2010**, 23, 183-93		23
1406	Application of Fragment Growing and Fragment Linking to the Discovery of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase. **2009**, 121, 8604-8608		13
1405	Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. **2009**, 48, 8452-6		120
1404	Chemically enabled synthesis of 2-amino-4-heteroarylpyrimidines. **2009**, 50, 2552-2554		8
1403	Facile synthesis of 4,5-disubstituted-3(2H)-pyridazinones. **2009**, 50, 2682-2684		5
1402	Structural models in the assessment of protein druggability based on HTS data. **2009**, 23, 583-92		17
1401	Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide. **2009**, 23, 527-39		67
1400	The multiple roles of computational chemistry in fragment-based drug design. **2009**, 23, 459-73		44
1399	Fragment-based drug discovery. **2009**, 23, 453-8		35
1398	Combinatorial library-based design with Basis Products. **2009**, 23, 725-36		12
1397	The rise of fragment-based drug discovery. **2009**, 1, 187-92		503

1396	Bioactivity-guided mapping and navigation of chemical space. **2009**, 5, 585-92		120
1395	The influence of lead discovery strategies on the properties of drug candidates. **2009**, 8, 203-12		466
1394	Identification of allosteric PIF-pocket ligands for PDK1 using NMR-based fragment screening and 1H-15N TROSY experiments. **2009**, 73, 179-88		51
1393	Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. **2009**, 74, 457-67		132
1392	Discovery and SAR of benzyl phenyl ethers as inhibitors of bacterial phenylalanyl-tRNA synthetase. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 665-9	2.9	18
1391	Synthesis and SAR of 4-substituted-2-aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2099-102	2.9	19
1390	3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2524-9	2.9	29
1389	Structure-based design of novel human Pin1 inhibitors (I). *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5613-6	2.9	72
1388	ADMET rules of thumb II: A comparison of the effects of common substituents on a range of ADMET parameters. **2009**, 17, 5906-19		93
1387	Antibacterial alkoxybenzamide inhibitors of the essential bacterial cell division protein FtsZ. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 524-7	2.9	75
1386	Matched molecular pair analysis of activity and properties of glycogen phosphorylase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 850-3	2.9	30
1385	(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 1991-5	2.9	26
1384	Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 2400-3	2.9	46
1383	3-(aminomethyl)piperazine-2,5-dione as a novel NMDA glycine site inhibitor from the chemical universe database GDB. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3832-5	2.9	21
1382	N-(Pyridin-2-yl) arylsulfonamide inhibitors of 11beta-hydroxysteroid dehydrogenase type 1: Discovery of PF-915275. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 3493-7	2.9	41
1381	Pyrazole NNRTIs 4: selection of UK-453,061 (lersivirine) as a development candidate. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 5857-60	2.9	82
1380	Synthesis and SAR of 2-phenyl-1-sulfonylaminocyclopropane carboxylates as ADAMTS-5 (Aggrecanase-2) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6213-7	2.9	15
1379	Discovery of novel non-peptide inhibitors of BACE-1 using virtual high-throughput screening. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6770-4	2.9	26

1378	Heteroaromatic rings of the future. *Journal of Medicinal Chemistry*, **2009**, 52, 2952-63	8.3	240
1377	Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. *Journal of Medicinal Chemistry*, **2009**, 52, 379-88	8.3	267
1376	Structure-based ligand design and the promise held for antiprotozoan drug discovery. **2009**, 284, 11749-53		40
1375	Rapid generation of a high quality lead for transforming growth factor-beta (TGF-beta) type I receptor (ALK5). *Journal of Medicinal Chemistry*, **2009**, 52, 7901-5	8.3	28
1374	Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs). *Journal of Medicinal Chemistry*, **2009**, 52, 4115-8	8.3	76
1373	Project-focused activity and knowledge tracker: a unified data analysis, collaboration, and workflow tool for medicinal chemistry project teams. *Journal of Chemical Information and Modeling*, **2009**, 49, 2639-49	6.1	15
1372	Identification of inhibitors of checkpoint kinase 1 through template screening. *Journal of Medicinal Chemistry*, **2009**, 52, 4810-9	8.3	34
1371	Identification of a brain penetrant PDE9A inhibitor utilizing prospective design and chemical enablement as a rapid lead optimization strategy. *Journal of Medicinal Chemistry*, **2009**, 52, 7946-9	8.3	62
1370	Review of recent acetyl-CoA carboxylase inhibitor patents: mid-2007-2008. **2009**, 19, 943-56		34
1369	Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics. *Journal of Medicinal Chemistry*, **2009**, 52, 4860-8	8.3	70
1368	Chapter 4 Case History: Chantix/Champix (Varenicline Tartrate), a Nicotinic Acetylcholine Receptor Partial Agonist as a Smoking Cessation Aid. **2009**, 71-101		14
1367	A structure-based approach to ligand discovery for 2C-methyl-D-erythritol-2,4-cyclodiphosphate synthase: a target for antimicrobial therapy. *Journal of Medicinal Chemistry*, **2009**, 52, 2531-42	8.3	16
1366	Conciliating binding efficiency and polypharmacology. **2009**, 30, 470-4		51
1365	Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine. **2009**, 131, 12949-59		94
1364	Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. *Journal of Medicinal Chemistry*, **2009**, 52, 7044-53	8.3	123
1363	Computational fragment-based approach at PDB scale by protein local similarity. *Journal of Chemical Information and Modeling*, **2009**, 49, 280-94	6.1	38
1362	Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). *Journal of Medicinal Chemistry*, **2009**, 52, 6433-46	8.3	78
1361	N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy. *Journal of Medicinal Chemistry*, **2009**, 52, 709-17	8.3	21

1360	Medicinal chemistry by the numbers: the physicochemistry, thermodynamics and kinetics of modern drug design. *Progress in Medicinal Chemistry*, **2009**, 48, 1-29	7.3	32
1359	Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. *ACS Chemical Biology*, **2009**, 4, 473-83	4.9	79
1358	Progress in the development of beta-secretase inhibitors for Alzheimer's disease. *Progress in Medicinal Chemistry*, **2009**, 48, 133-61	7.3	31
1357	Fragment-Based Drug Discovery in Academia: Experiences From a Tuberculosis Programme. **2009**, 21-36		3
1356	Theory of free energy and entropy in noncovalent binding. **2009**, 109, 4092-107		291
1355	Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. *Journal of Medicinal Chemistry*, **2009**, 52, 5188-96	8.3	175
1354	Searching chemical space with the Bayesian Idea Generator. *Journal of Chemical Information and Modeling*, **2009**, 49, 2211-20	6.1	10
1353	From Molecules to Medicines. **2009**,		
1352	Overview of Hit to Lead: The Medicinal Chemist's Role from HTS Retest to Lead Optimization Hand Off. **2009**, 1-24		3
1351	Fragment-Based Drug Discovery of Kinase Inhibitors. 461-483		2
1350	Tykerb Discovery: A Dual EGFR and ERBB2 Tyrosine Kinase Inhibitor. 41-56		
1349	One scaffold, three binding modes: novel and selective pteridine reductase 1 inhibitors derived from fragment hits discovered by virtual screening. *Journal of Medicinal Chemistry*, **2009**, 52, 4454-65	8.3	78
1348	Discovery of potent and selective inhibitors of the mammalian target of rapamycin (mTOR) kinase. *Journal of Medicinal Chemistry*, **2009**, 52, 7081-9	8.3	48
1347	Azaindole hydroxamic acids are potent HIV-1 integrase inhibitors. *Journal of Medicinal Chemistry*, **2009**, 52, 7211-9	8.3	44
1346	Advances in fragment-based drug discovery platforms. **2009**, 4, 1125-44		25
1345	Advances in Nuclear Magnetic Resonance for Drug Discovery. **2009**, 4, 1077-1098		35
1344	Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design. *Journal of Chemical Information and Modeling*, **2009**, 49, 1211-22	6.1	15
1343	Virtual screening against alpha-cobratoxin. **2009**, 14, 1109-18		17

1342	Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist. *Journal of Medicinal Chemistry*, **2009**, 52, 234-7	8.3	58
1341	Thioamide hydroxypyrothiones supersede amide hydroxypyrothiones in potency against anthrax lethal factor. *Journal of Medicinal Chemistry*, **2009**, 52, 1063-74	8.3	42
1340	Structure-Based Design and Characterization of Axitinib. 167-201		8
1339	Fragment-based discovery of inhibitors of protein kinase B. **2009**, 9, 1705-17		10
1338	Hit triage using efficiency indices after screening of compound libraries in drug discovery. **2009**, 9, 1718-24		14
1337	[Fragment-based drug discovery: concept and aim]. **2010**, 130, 315-23		3
1336	[In-silico approaches for fragment-based drug design]. **2010**, 130, 349-54		0
1335	Fragment-Based Drug Design: Considerations for Good ADME Properties. **2010**, 417-485		
1334	Protein□Protein Interactions as Drug Discovery Targets. **2010**, 335-366		
1333	De novo drug design. **2011**, 672, 299-323		87
1332	Some Trends in Chem(o)informatics. **2011**, 672, 1-37		15
1331	Enthalpic efficiency of ligand binding. *Journal of Chemical Information and Modeling*, **2010**, 50, 1536-41	6.1	51
1330	Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. *Journal of Medicinal Chemistry*, **2010**, 53, 1799-809	8.3	211
1329	Lipophilicity in drug discovery. **2010**, 5, 235-48		526
1328	An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. *Journal of Medicinal Chemistry*, **2010**, 53, 2986-97	8.3	163
1327	Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor □ ligands. *Journal of Medicinal Chemistry*, **2010**, 53, 7192-201	8.3	30
1326	Structural biology in fragment-based drug design. **2010**, 20, 497-507		173
1325	Higher throughput calorimetry: opportunities, approaches and challenges. **2010**, 20, 598-605		82

1324	Evolving molecules using multi-objective optimization: applying to ADME/Tox. *Drug Discovery Today*, **2010**, 15, 451-60	8.8	68
1323	Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation. *Drug Discovery Today*, **2010**, 15, 804-11	8.8	84
1322	Thermodynamics guided lead discovery and optimization. *Drug Discovery Today*, **2010**, 15, 919-32	8.8	111
1321	Screening-based discovery of drug-like O-GlcNAcase inhibitor scaffolds. **2010**, 584, 694-700		23
1320	Fragmenting the S100B-p53 interaction: combined virtual/biophysical screening approaches to identify ligands. **2010**, 5, 428-35		19
1319	Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression. **2010**, 5, 200-5		6
1318	Pyrrolidine derivatives as plasmepsin inhibitors: binding mode analysis assisted by molecular dynamics simulations of a highly flexible protein. **2010**, 5, 443-54		14
1317	Chelator fragment libraries for targeting metalloproteinases. **2010**, 5, 195-9		53
1316	Fragment-based lead discovery: screening and optimizing fragments for thermolysin inhibition. **2010**, 5, 930-40		18
1315	Discovery of a novel Hsp90 inhibitor by fragment linking. **2010**, 5, 1697-700		42
1314	Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations. **2010**, 62, 724-31		86
1313	Drug efficiency indices for improvement of molecular docking scoring functions. **2010**, 31, 174-84		46
1312	High Throughput Screening Approach to Lead Discovery. **2010**, 21-71		4
1311	Fragment-Based Lead Discovery. **2010**, 105-139		3
1310	Multistep virtual screening for rapid and efficient identification of non-nucleoside bacterial thymidine kinase inhibitors. **2010**, 16, 9630-7		8
1309	QM methods in structure based design: utility in probing protein-ligand interactions. **2010**, 29, 507-17		5
1308	Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 586-90	2.9	59
1307	Synthesis and SAR of novel imidazoles as potent and selective cannabinoid CB2 receptor antagonists with high binding efficiencies. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1084-9	2.9	22

1306	Iodine(III)-mediated ring expansion: an efficient and green pathway in the synthesis of a key precursor for the design of aminopeptidase (APN or CD13) inhibitors. **2010**, 66, 8722-8728		7
1305	Drugging challenging targets using fragment-based approaches. **2010**, 14, 299-307		70
1304	Natural product-guided discovery of a fungal chitinase inhibitor. **2010**, 17, 1275-81		32
1303	Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. **2010**, 18, 707-18		44
1302	Synthesis and optimization of thiadiazole derivatives as a novel class of substrate competitive c-Jun N-terminal kinase inhibitors. **2010**, 18, 590-6		17
1301	Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. **2010**, 18, 5056-62		22
1300	Acetazolamide-based fungal chitinase inhibitors. **2010**, 18, 8334-40		37
1299	Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2383-8	2.9	46
1298	Design and synthesis of orally-active and selective azaindane 5HT2c agonist for the treatment of obesity. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 266-71	2.9	19
1297	Oxygenated analogues of UK-396082 as inhibitors of activated thrombin activatable fibrinolysis inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 92-6	2.9	8
1296	Discovery and initial optimization of 5,5'-disubstituted aminohydantoins as potent beta-secretase (BACE1) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 632-5	2.9	28
1295	3-Aryl-4-(arylhydrazono)-1H-pyrazol-5-ones: Highly ligand efficient and potent inhibitors of GSK3beta. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1661-4	2.9	46
1294	Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 1543-7	2.9	23
1293	Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesity. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2365-9	2.9	7
1292	Structure-based design of novel human Pin1 inhibitors (II). *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 2210-4	2.9	66
1291	The discovery and SAR of indoline-3-carboxamides--a new series of 5-HT6 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 3713-6	2.9	11
1290	Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4045-9	2.9	22
1289	NF-kappaB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 4515-20	2.9	43

1288	S-benzylisothiourea derivatives as small-molecule inhibitors of indoleamine-2,3-dioxygenase. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5126-9	2.9	35
1287	Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 5988-93	2.9	26
1286	Triazolyl tryptoline derivatives as β-secretase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 6572-6	2.9	20
1285	Identification of potent ITK inhibitors through focused compound library design including structural information. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 6998-7003	2.9	16
1284	The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead. *Bioorganic and Medicinal Chemistry Letters*, **2010**, 20, 7421-5	2.9	21
1283	Novel insights for dihydroorotate dehydrogenase class 1A inhibitors discovery. **2010**, 45, 5899-909		36
1282	In-crystal chemical ligation for lead compound generation. **2010**, 43, 1329-1337		6
1281	The impact of GPCR structures on pharmacology and structure-based drug design. **2010**, 159, 986-96		109
1280	Fragment-based screen against HIV protease. **2010**, 75, 257-68		57
1279	Fragment-based discovery of novel thymidylate synthase leads by NMR screening and group epitope mapping. **2010**, 76, 218-33		11
1278	Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative. **2010**, 76, 305-13		14
1277	Adding calorimetric data to decision making in lead discovery: a hot tip. **2010**, 9, 23-7		315
1276	. **2010**,		25
1275	In Silico Screening. **2010**, 211-235		
1274	. **2010**,		2
1273	. **2010**,		4
1272	Tipranavir, a Non-Peptidic Protease Inhibitor for Multi-Drug Resistant HIV. **2010**, 443-463		
1271	NMR in fragment-based drug discovery. 41-58		2

1270	Identification of selective enzyme inhibitors by fragment library screening. **2010**, 15, 1042-50		17
1269	Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates. **2010**, 5, 609-18		39
1268	Identification and characterization of novel NMDA receptor antagonists selective for NR2A- over NR2B-containing receptors. **2010**, 335, 636-44		102
1267	Target immobilization as a strategy for NMR-based fragment screening: comparison of TINS, STD, and SPR for fragment hit identification. **2010**, 15, 978-89		35
1266	New Techniques to Express and Crystallize G Protein-Coupled Receptors. **2010**, 324-384		1
1265	Multiobjective Optimization for Drug Discovery. **2010**, 259-278		
1264	SNP analysis of Rac1 For personalized ligand interaction. **2010**, 2010, 1779-82		
1263	Virtual Screening. **2010**, 1-46		1
1262	NMR-Based Screening and Drug Discovery. **2010**, 367-446		2
1261	Inhibitors of Leishmania GDP-mannose pyrophosphorylase identified by high-throughput screening of small-molecule chemical library. **2010**, 54, 1712-9		34
1260	Contributions of computational chemistry and biophysical techniques to fragment-based drug discovery. **2010**, 17, 1769-94		36
1259	Computational approaches for fragment-based and de novo design. **2010**, 10, 14-32		87
1258	Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 942-50	8.3	93
1257	Fragment-Based Approaches for Identification of BACE Inhibitors. 107-121		1
1256	Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks. **2010**, 380-391		59
1255	Ligand specificity in fragment-based drug design. *Journal of Medicinal Chemistry*, **2010**, 53, 5256-66	8.3	44
1254	Rational design of indoleamine 2,3-dioxygenase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 1172-89	8.3	126
1253	Ligand efficiency as a guide in fragment hit selection and optimization. **2010**, 7, e147-202		121

1252	Fragments: past, present and future. **2010**, 7, e147-202		38
1251	The heat is on: thermodynamic analysis in fragment-based drug discovery. **2010**, 7, e147-202		16
1250	Cheminformatic tools for medicinal chemists. *Journal of Medicinal Chemistry*, **2010**, 53, 4830-41	8.3	63
1249	Structural studies of pterin-based inhibitors of dihydropteroate synthase. *Journal of Medicinal Chemistry*, **2010**, 53, 166-77	8.3	62
1248	Measuring binding kinetics of ligands with tethered receptors by fluorescence polarization and total internal reflection fluorescence. **2010**, 82, 3819-25		17
1247	Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469. *ACS Medicinal Chemistry Letters*, **2010**, 1, 345-9	4.3	53
1246	Oral oxytocin antagonists. *Journal of Medicinal Chemistry*, **2010**, 53, 6525-38	8.3	29
1245	Recent Advances in Acetyl-CoA Carboxylase Inhibitors. **2010**, 45, 95-108		8
1244	Compound Collection Enhancement and Paradigms for High-Throughput Screening an Update. **2010**, 45, 409-428		12
1243	Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. *Journal of Medicinal Chemistry*, **2010**, 53, 573-85	8.3	52
1242	Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. *ACS Medicinal Chemistry Letters*, **2010**, 1, 439-42	4.3	24
1241	Fragment screening by surface plasmon resonance. *ACS Medicinal Chemistry Letters*, **2010**, 1, 44-8	4.3	112
1240	Virtual Screening with AutoDock: Theory and Practice. **2010**, 5, 597-607		326
1239	Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. *Journal of Medicinal Chemistry*, **2010**, 53, 5942-55	8.3	154
1238	Fragment library design: efficiently hunting drugs in chemical space. **2010**, 7, e147-202		30
1237	Personalized medicine: the impact on chemistry. **2010**, 1, 651-65		6
1236	Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. *Journal of Chemical Information and Modeling*, **2010**, 50, 906-23	6.1	26
1235	Fragment-based deconstruction of Bcl-xL inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 2577-88	8.3	56

1234	Reducing the Risk of Drug Attrition Associated with Physicochemical Properties. **2010**, 45, 393-407		56
1233	In silico fragment-based drug design. **2010**, 5, 1047-65		19
1232	Calorimetry as a tool for understanding biomolecular interactions and an aid to drug design. **2010**, 38, 888-93		74
1231	Discovery of novel antibacterials. **2010**, 5, 145-54		27
1230	Design, synthesis, and structure-activity relationships of 3-ethynyl-1H-indazoles as inhibitors of the phosphatidylinositol 3-kinase signaling pathway. *Journal of Medicinal Chemistry*, **2010**, 53, 8368-75	8.3	22
1229	Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. *Journal of Medicinal Chemistry*, **2010**, 53, 951-65	8.3	110
1228	Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach. *Journal of Medicinal Chemistry*, **2010**, 53, 6618-28	8.3	30
1227	A fragment-based approach to identifying ligands for riboswitches. *ACS Chemical Biology*, **2010**, 5, 355-8	4.9	42
1226	Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. *Journal of Medicinal Chemistry*, **2010**, 53, 7682-98	8.3	53
1225	Development of small-molecule therapies for autoimmune diseases. **2010**, 43, 526-38		5
1224	Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. **2011**, 348, 25-59		50
1223	Fragment screening against the thiamine pyrophosphate riboswitchthiM. **2011**, 2, 157-165		41
1222	Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose. **2011**, 6, 913-20		20
1221	Identification of novel ligands for thiamine pyrophosphate (TPP) riboswitches. **2011**, 39, 652-7		17
1220	Robust central reduction of amyloid-□n humans with an orally available, non-peptidic □ecretase inhibitor. **2011**, 31, 16507-16		307
1219	Global free energy scoring functions based on distance-dependent atom-type pair descriptors. *Journal of Chemical Information and Modeling*, **2011**, 51, 707-20	6.1	24
1218	Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. *Journal of Medicinal Chemistry*, **2011**, 54, 4536-47	8.3	46
1217	The use of GPCR structures in drug design. **2011**, 62, 1-36		34

1216	Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1). *Journal of Medicinal Chemistry*, **2011**, 54, 8490-500	8.3	25
1215	Experiences in fragment-based lead discovery. **2011**, 493, 509-31		95
1214	Fragment screening using X-ray crystallography. **2012**, 317, 33-59		60
1213	Combining biophysical screening and X-ray crystallography for fragment-based drug discovery. **2012**, 317, 115-43		37
1212	Druggability assessment of protein-protein interfaces. **2011**, 3, 2021-38		34
1211	Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties. *Journal of Medicinal Chemistry*, **2011**, 54, 6691-703	8.3	58
1210	SERAPhiC: a benchmark for in silico fragment-based drug design. *Journal of Chemical Information and Modeling*, **2011**, 51, 2882-96	6.1	15
1209	Emerging trends in metalloprotein inhibition. **2011**, 40, 3445-54		57
1208	Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. *Journal of Medicinal Chemistry*, **2011**, 54, 709-18	8.3	17
1207	Design and discovery of a selective small molecule δ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242). *Journal of Medicinal Chemistry*, **2011**, 54, 5868-77	8.3	37
1206	Identifying chelators for metalloprotein inhibitors using a fragment-based approach. *Journal of Medicinal Chemistry*, **2011**, 54, 591-602	8.3	106
1205	AUDocker LE: A GUI for virtual screening with AUTODOCK Vina. **2011**, 4, 445		48
1204	Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. **2011**, 62, 175-218		41
1203	A practical use of ligand efficiency indices out of the fragment-based approach: ligand efficiency-guided lead identification of soluble epoxide hydrolase inhibitors. *Journal of Medicinal Chemistry*, **2011**, 54, 851-7	8.3	53
1202	Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. **2011**, 133, 5363-71		63
1201	Fragment-Based Approaches in Virtual Screening. **2011**, 467-489		2
1200	Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors. *ACS Medicinal Chemistry Letters*, **2011**, 2, 34-8	4.3	25
1199	Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). **2011**, 2, 450-70		52

1198	Using computational techniques in fragment-based drug discovery. **2011**, 493, 137-55		10
1197	How well can fragments explore accessed chemical space? A case study from heat shock protein 90. *Journal of Medicinal Chemistry*, **2011**, 54, 3989-4005	8.3	64
1196	Designing a diverse high-quality library for crystallography-based FBDD screening. **2011**, 493, 3-20		16
1195	Lead generation and examples opinion regarding how to follow up hits. **2011**, 493, 383-419		31
1194	Fragment screening of infectious disease targets in a structural genomics environment. **2011**, 493, 533-56		5
1193	Effective progression of nuclear magnetic resonance-detected fragment hits. **2011**, 493, 447-68		4
1192	Chemoinformatics and Computational Chemical Biology. **2011**,		6
1191	Rational methods for the selection of diverse screening compounds. *ACS Chemical Biology*, **2011**, 6, 208-17	4.9	80
1190	Quality by design in lead optimization: a new strategy to address productivity in drug discovery. **2011**, 11, 515-20		5
1189	Design of screening collections for successful fragment-based lead discovery. **2011**, 685, 219-40		2
1188	Introduction to fragment-based drug discovery. **2012**, 317, 1-32		142
1187	Computational medicinal chemistry in fragment-based drug discovery: what, how and when. **2011**, 3, 95-134		16
1186	Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors. **2012**, 317, 83-114		44
1185	Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. **2011**, 24, 1420-56		371
1184	Fragment-based approaches and computer-aided drug discovery. **2012**, 317, 201-22		22
1183	Emerging role of surface plasmon resonance in fragment-based drug discovery. **2011**, 3, 1809-20		44
1182	Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. *Journal of Medicinal Chemistry*, **2011**, 54, 699-708	8.3	37
1181	Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrol *Journal of Medicinal Chemistry*, **2011**, 54, 3368-85	8.3	32

1180	Progress in structure based drug design for G protein-coupled receptors. *Journal of Medicinal Chemistry*, **2011**, 54, 4283-311	8.3	191
1179	Dihydroquinazolines as a novel class of Trypanosoma brucei trypanothione reductase inhibitors: discovery, synthesis, and characterization of their binding mode by protein crystallography. *Journal of Medicinal Chemistry*, **2011**, 54, 6514-30	8.3	91
1178	Progress in structure-based drug design against influenza A virus. **2011**, 6, 619-31		12
1177	Biophysical mapping of the adenosine A2A receptor. *Journal of Medicinal Chemistry*, **2011**, 54, 4312-23	8.3	99
1176	Target Profile Prediction and Practical Evaluation of a Biginelli-Type Dihydropyrimidine Compound Library. *Pharmaceuticals*, **2011**, 4, 1236-1247	5.2	11
1175	Targeting protein-protein interactions and fragment-based drug discovery. **2012**, 317, 145-79		79
1174	Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. *Journal of Medicinal Chemistry*, **2011**, 54, 4781-92	8.3	61
1173	Structure of trans-resveratrol in complex with the cardiac regulatory protein troponin C. **2011**, 50, 1309-20		28
1172	Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin. **2011**, 9, 5778-86		52
1171	DrugPred: a structure-based approach to predict protein druggability developed using an extensive nonredundant data set. *Journal of Chemical Information and Modeling*, **2011**, 51, 2829-42	6.1	66
1170	Nature of allosteric inhibition in glutamate racemase: discovery and characterization of a cryptic inhibitory pocket using atomistic MD simulations and pKa calculations. **2011**, 115, 3416-24		19
1169	Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors. **2011**, 46, 4808-19		20
1168	. **2011**,		26
1167	Central Modulation of Circadian Rhythm via CK1 Inhibition for Psychiatric Indications. **2011**, 46, 33-51		3
1166	Fragment-Based Ligand Discovery. 74-86		
1165	. **2011**,		6
1164	. **2011**,		13
1163	. **2011**,		19

1162	The design and application of target-focused compound libraries. **2011**, 14, 521-31		82
1161	Modern drug discovery technologies: opportunities and challenges in lead discovery. **2011**, 14, 830-9		31
1160	Discovery of modulators of protein-protein interactions: current approaches and limitations. **2011**, 11, 248-57		60
1159	Structural investigation of inhibitor designs targeting 3-dehydroquinate dehydratase from the shikimate pathway of Mycobacterium tuberculosis. **2011**, 436, 729-39		33
1158	Collation and data-mining of literature bioactivity data for drug discovery. **2011**, 39, 1365-70		27
1157	Azaindole Hydroxamic Acids are HIV-1 Integrase Inhibitors. **2011**, 265-274		
1156	The Pyramid Approach to Fragment-Based Biophysical Screening. **2011**, 241-253		2
1155	SPR Screening of Chemical Microarrays for Fragment-Based Discovery. **2011**, 41-55		1
1154	Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. **2011**, 77, 268-71		12
1153	Structure-activity relationship investigations of leishmanicidal N-benzylcytisine derivatives. **2011**, 78, 183-9		5
1152	Probing the links between in vitro potency, ADMET and physicochemical parameters. **2011**, 10, 197-208		333
1151	The resurgence of covalent drugs. **2011**, 10, 307-17		1114
1150	A molecular informatics view on best practice in multi-parameter compound optimization. *Drug Discovery Today*, **2011**, 16, 555-68	8.8	16
1149	Kinetic efficiency: the missing metric for enhancing compound quality?. *Drug Discovery Today*, **2011**, 16, 910-3	8.8	36
1148	Convolutamines I and J, antitrypanosomal alkaloids from the bryozoan Amathia tortusa. **2011**, 19, 6615-9		27
1147	A novel amino-benzosuberone derivative is a picomolar inhibitor of mammalian aminopeptidase N/CD13. **2011**, 19, 5716-33		21
1146	Identification of pyridazin-3-one derivatives as potent, selective histamine H receptor inverse agonists with robust wake activity. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5493-7	2.9	19
1145	Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5487-92	2.9	15

1144	Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5480-6	2.9	14
1143	Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H and the ion channel serotonin 5-HT. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5460-4	2.9	30
1142	Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR). *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6591-5	2.9	5
1141	Fragment based discovery of a novel and selective PI3 kinase inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6586-90	2.9	28
1140	Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6596-602	2.9	26
1139	Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 5778-83	2.9	22
1138	Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6031-5	2.9	4
1137	Discovery of pyrazoles as novel FPR1 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6456-60	2.9	9
1136	Discovery of potent, selective, orally active benzoxazepine-based Orexin-2 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6414-6	2.9	25
1135	Discovery of spiropiperidine-based potent and selective Orexin-2 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6409-13	2.9	13
1134	Investigation of the pyrazinones as PDE5 inhibitors: evaluation of regioisomeric projections into the solvent region. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6348-52	2.9	10
1133	The successful quest for oral factor Xa inhibitors; learnings for all of medicinal chemistry?. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 6228-35	2.9	17
1132	Fragment-Based Drug Discovery for Diseases of the Central Nervous System. **2011**, 179-192		
1131	Fragment-Based High-Throughput Docking and Library Tailoring. **2011**, 131-147		
1130	Chapter 2:Contemporary Approaches to Kinase Lead Generation. **2011**, 54-78		
1129	Synthesis and pharmacological characterization of bicyclic triple reuptake inhibitor 3-aryl octahydrocyclopenta[c]pyrrole analogues. *Journal of Medicinal Chemistry*, **2011**, 54, 5283-95	8.3	15
1128	Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. *Journal of Medicinal Chemistry*, **2011**, 54, 8328-42	8.3	41
1127	Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone. *Journal of Medicinal Chemistry*, **2011**, 54, 7206-19	8.3	37

1126	Docking performance of fragments and druglike compounds. *Journal of Medicinal Chemistry*, **2011**, 54, 5422-31	8.3	94
1125	Preparing and Filtering Compound Databases for Virtual and Experimental Screening. **2011**, 35-59		6
1124	Combined approach using ligand efficiency, cross-docking, and antitarget hits for wild-type and drug-resistant Y181C HIV-1 reverse transcriptase. *Journal of Chemical Information and Modeling*, **2011**, 51, 2595-611	6.1	24
1123	Structure-guided fragment-based in silico drug design of dengue protease inhibitors. **2011**, 25, 263-74		46
1122	Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics. **2011**, 25, 621-36		50
1121	Assessing the lipophilicity of fragments and early hits. **2011**, 25, 663-7		82
1120	A comparative study of fragment screening methods on the p38α kinase: new methods, new insights. **2011**, 25, 677-87		30
1119	Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery. **2011**, 25, 689-98		14
1118	Design of a fragment library that maximally represents available chemical space. **2011**, 25, 611-20		33
1117	Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. **2011**, 19, 3569-78		13
1116	Molecular dynamics simulations and in silico peptide ligand screening of the Elk-1 ETS domain. **2011**, 3, 49		4
1115	In-crystal affinity ranking of fragment hit compounds reveals a relationship with their inhibitory activities. **2011**, 44, 798-804		15
1114	Retrospective Mapping of SAR Data for TTR Protein in Chemico-Biological Space Using Ligand Efficiency Indices as a Guide to Drug Discovery Strategies. **2011**, 30, 161-7		4
1113	Time-Trajectories in Efficiency Maps as Effective Guides for Drug Discovery Efforts. **2011**, 30, 137-44		4
1112	Ligand Efficiency Indices (LEIs): More than a Simple Efficiency Yardstick. **2011**, 30, 122-32		21
1111	Hybrid Steered Molecular Dynamics-Docking: An Efficient Solution to the Problem of Ranking Inhibitor Affinities Against a Flexible Drug Target. **2011**, 30, 459-471		26
1110	From Hits to Leads: Challenges for the Next Phase of Machine Learning in Medicinal Chemistry. **2011**, 30, 759-63		2
1109	Identification and Application of Antitarget Activity Hotspots to Guide Compound Optimization. **2011**, 30, 996-1008		5

1108	Fragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1. **2011**, 6, 258-61		22
1107	Identification of novel matrix metalloproteinase inhibitors by screening of phenol fragments library. **2011**, 344, 557-63		19
1106	Molecular complexity and fragment-based drug discovery: ten years on. **2011**, 15, 489-96		129
1105	Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). **2011**, 15, 475-81		162
1104	Amino-benzosuberone: a novel warhead for selective inhibition of human aminopeptidase-N/CD13. **2011**, 19, 1434-49		29
1103	Synthesis and biological evaluation of α-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture. **2011**, 19, 4067-74		96
1102	Reverse type I inhibitor of Mycobacterium tuberculosis CYP125A1. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 332-7	2.9	24
1101	Non-covalent inhibitors of rhinovirus 3C protease. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 777-80	2.9	22
1100	Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1270-4	2.9	28
1099	High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2646-9	2.9	13
1098	6-amino-4-(pyrimidin-4-yl)pyridones: novel glycogen synthase kinase-3β inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 1429-33	2.9	24
1097	The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3050-6	2.9	51
1096	Discovery of small molecule human FPR1 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 2991-7	2.9	16
1095	Design strategies to target crystallographic waters applied to the Hsp90 molecular chaperone. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 3557-62	2.9	34
1094	Selective non zinc binding inhibitors of MMP13. *Bioorganic and Medicinal Chemistry Letters*, **2011**, 21, 4215-9	2.9	19
1093	Design and synthesis of protein-protein interaction mimics as Plasmodium falciparum cysteine protease, falcipain-2 inhibitors. **2011**, 46, 2083-90		19
1092	2,4-Diamino-5-(2'-arylpropargyl)pyrimidine derivatives as new nonclassical antifolates for human dihydrofolate reductase inhibition. **2011**, 29, 608-13		12
1091	Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation. **2011**, 29, 843-64		13

1090	The benefits of constructing leads from fragment hits. **2011**, 3, 1111-5		25
1089	Fragment-based drug design: computational & experimental state of the art. **2011**, 14, 500-20		27
1088	NMR screening and hit validation in fragment based drug discovery. **2011**, 11, 43-67		46
1087	Potent, selective inhibitors of fibroblast growth factor receptor define fibroblast growth factor dependence in preclinical cancer models. **2011**, 10, 1542-52		26
1086	Matrix-based multiparameter optimisation of glucokinase activators: the discovery of AZD1092. **2011**, 2, 775		30
1085	Selective orthosteric free fatty acid receptor 2 (FFA2) agonists: identification of the structural and chemical requirements for selective activation of FFA2 versus FFA3. **2011**, 286, 10628-40		87
1084	Design Principles of Deep Pocket-Targeting Protein Kinase Inhibitors. **2011**, 145-193		2
1083	Fragment-based screening by protein crystallography: successes and pitfalls. *International Journal of Molecular Sciences*, **2012**, 13, 12857-79	6.3	40
1082	Selective inhibitors of protozoan protein N-myristoyltransferases as starting points for tropical disease medicinal chemistry programs. **2012**, 6, e1625		58
1081	Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents. **2012**, 56, 1240-6		88
1080	Recent advances in plasmepsin medicinal chemistry and implications for future antimalarial drug discovery efforts. **2012**, 12, 445-55		46
1079	Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. **2012**, 12, 1500-13		40
1078	Molecular property filters describing pharmacokinetics and drug binding. **2012**, 19, 1646-62		31
1077	Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. **2012**, 45, 383-426		74
1076	Fragment based drug design: from experimental to computational approaches. **2012**, 19, 5128-47		94
1075	Aminoacyl-tRNA synthetase inhibitors as potent antibacterials. **2012**, 19, 3550-63		24
1074	Using fragment-based technologies to target protein-protein interactions. **2012**, 18, 4685-96		25
1073	Targeting cancer using fragment based drug discovery. **2012**, 12, 40-8		6

1072	Multi-parameter optimization: identifying high quality compounds with a balance of properties. **2012**, 18, 1292-310		91
1071	Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia. **2012**, 120, 4461-9		134
1070	The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 7302-5	2.9	14
1069	Application of structure-based drug design and parallel chemistry to identify selective, brain penetrant, in vivo active phosphodiesterase 9A inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 9055-68	8.3	48
1068	New aminoimidazoles as β-secretase (BACE-1) inhibitors showing amyloid-β (Aβ) lowering in brain. *Journal of Medicinal Chemistry*, **2012**, 55, 9297-311	8.3	63
1067	Comparative analysis of Rac1 binding efficiency with different classes of ligands: morpholines, flavonoids and imidazoles. **2012**, 11, 181-7		3
1066	Identification and In-Vitro ADME Assessment of a Series of Novel Anti-Malarial Agents Suitable for Hit-to-Lead Chemistry. *ACS Medicinal Chemistry Letters*, **2012**, 3, 570-3	4.3	14
1065	DrugLogit: logistic discrimination between drugs and nondrugs including disease-specificity by assigning probabilities based on molecular properties. *Journal of Chemical Information and Modeling*, **2012**, 52, 2165-80	6.1	33
1064	Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. *Journal of Medicinal Chemistry*, **2012**, 55, 1898-903	8.3	263
1063	Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 10090-107	8.3	64
1062	Identification of novel adenosine A(2A) receptor antagonists by virtual screening. *Journal of Medicinal Chemistry*, **2012**, 55, 1904-9	8.3	110
1061	Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization. **2012**, 10, 7402-17		19
1060	Evaluating the enthalpic contribution to ligand binding using QM calculations: effect of methodology on geometries and interaction energies. **2012**, 10, 7053-61		7
1059	Significance estimation for sequence-based chemical similarity searching (PhAST) and application to AuroraA kinase inhibitors. **2012**, 4, 1897-906		4
1058	Virtual fragment screening: exploration of MM-PBSA re-scoring. **2012**, 26, 921-34		7
1057	Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. **2012**, 19, 1105-15		67
1056	Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-protein interface. **2012**, 19, 1300-12		129
1055	Property based optimisation of glucokinase activators: discovery of the phase IIb clinical candidate AZD1656. **2012**, 3, 1077		28

1054	3-aminopiperidine-based peptide analogues as the first selective noncovalent inhibitors of the bacterial cysteine protease IdeS. *Journal of Medicinal Chemistry*, **2012**, 55, 2549-60	8.3	9
1053	Fighting high molecular weight in bioactive molecules with sub-pharmacophore-based virtual screening. *Journal of Chemical Information and Modeling*, **2012**, 52, 380-90	6.1	
1052	Binding efficiency of protein-protein complexes. **2012**, 51, 9124-36		31
1051	Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. *Journal of Medicinal Chemistry*, **2012**, 55, 9831-7	8.3	157
1050	Fragment screening using capillary electrophoresis (CEfrag) for hit identification of heat shock protein 90 ATPase inhibitors. **2012**, 17, 868-76		41
1049	Druggability Assessment of Allosteric Proteins by Dynamics Simulations in the Presence of Probe Molecules. **2012**, 8, 2435-2447		113
1048	Experiences in fragment-based drug discovery. **2012**, 33, 224-32		205
1047	Synthesis, biological activity and docking study of some new isatin Schiff base derivatives. **2012**, 21, 3730-3740		35
1046	Rational design of 4-aryl-1,2,3-triazoles for indoleamine 2,3-dioxygenase 1 inhibition. *Journal of Medicinal Chemistry*, **2012**, 55, 5270-90	8.3	129
1045	Identification of influenza endonuclease inhibitors using a novel fluorescence polarization assay. *ACS Chemical Biology*, **2012**, 7, 526-34	4.9	62
1044	Fragment-based screening for inhibitors of PDE4A using enthalpy arrays and X-ray crystallography. **2012**, 17, 469-80		19
1043	Virtual screening against acetylcholine binding protein. **2012**, 17, 204-15		8
1042	Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1. *Journal of Medicinal Chemistry*, **2012**, 55, 8745-56	8.3	46
1041	Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4396-403	2.9	13
1040	Discovery of triazolopyrimidine-based PDE8B inhibitors: exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5721-6	2.9	20
1039	2-Phenylamino-6-cyano-1H-benzimidazole-based isoform selective casein kinase 1 gamma (CK1γ) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 5392-5	2.9	16
1038	Discovery of a novel and potent class of F. tularensis enoyl-reductase (FabI) inhibitors by molecular shape and electrostatic matching. *Journal of Medicinal Chemistry*, **2012**, 55, 268-79	8.3	55
1037	Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening. *Journal of Chemical Information and Modeling*, **2012**, 52, 2730-40	6.1	27

1036	Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. *ACS Medicinal Chemistry Letters*, **2012**, 3, 715-720	4.3	15
1035	In vitro measurement of drug efficiency index to aid early lead optimization. **2012**, 101, 4155-69		28
1034	Discovery of Brain-Penetrant, Irreversible Kynurenine Aminotransferase II Inhibitors for Schizophrenia. *ACS Medicinal Chemistry Letters*, **2012**, 3, 187-92	4.3	69
1033	Statistical Thermodynamics of Binding and Molecular Recognition Models. **2012**, 1-22		2
1032	Acyl guanidine inhibitors of β-secretase (BACE-1): optimization of a micromolar hit to a nanomolar lead via iterative solid- and solution-phase library synthesis. *Journal of Medicinal Chemistry*, **2012**, 55, 9208-23	8.3	36
1031	Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. *Journal of Medicinal Chemistry*, **2012**, 55, 140-52	8.3	88
1030	Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. *Journal of Medicinal Chemistry*, **2012**, 55, 7010-20	8.3	42
1029	CHAPTER 18:Medicinal Chemistry Challenges in CNS Drug Discovery. **2012**, 465-509		5
1028	Ligand-receptor interaction platforms and their applications for drug discovery. **2012**, 7, 969-88		81
1027	Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kδ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. *Journal of Medicinal Chemistry*, **2012**, 55, 4788-805	8.3	47
1026	Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. **2012**, 20, 5324-42		58
1025	Discovery of structurally-diverse inhibitor scaffolds by high-throughput screening of a fragment library with dimethylarginine dimethylaminohydrolase. **2012**, 20, 5550-8		12
1024	Design and synthesis of 2(1H)-pyrazinones as inhibitors of protein kinases. **2012**, 68, 9713-9728		13
1023	Discovery of small molecule cancer drugs: successes, challenges and opportunities. *Molecular Oncology*, **2012**, 6, 155-76	7.9	363
1022	Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. **2012**, 134, 6810-8		159
1021	Guiding principles for natural product drug discovery. **2012**, 4, 1067-84		33
1020	Identification of a glutathione peroxidase inhibitor that reverses resistance to anticancer drugs in human B-cell lymphoma cell lines. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 6712-5	2.9	19
1019	Free fatty acid receptor 1 (FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophilicity and improves ADME properties. *Journal of Medicinal Chemistry*, **2012**, 55, 6624-8	8.3	47

1018	Protein-Protein Interactions as Drug Targets. **2012**, 1-55		3
1017	Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. *Journal of Medicinal Chemistry*, **2012**, 55, 5151-64	8.3	57
1016	From triclosan toward the clinic: discovery of nonbiocidal, potent FabI inhibitors for the treatment of resistant bacteria. *Journal of Medicinal Chemistry*, **2012**, 55, 9914-28	8.3	61
1015	Simplified platensimycin analogues as antibacterial agents. **2012**, 3, 244-249		1
1014	Preparation and optimization of new 4-(morpholin-4-yl)-(6-oxo-1,6-dihydropyrimidin-2-yl)amide derivatives as PI3K□inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 6381-4	2.9	17
1013	Hot spot analysis for driving the development of hits into leads in fragment-based drug discovery. *Journal of Chemical Information and Modeling*, **2012**, 52, 199-209	6.1	45
1012	Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation. *Journal of Medicinal Chemistry*, **2012**, 55, 3285-306	8.3	125
1011	Emac □a comparative index for the assessment of macrocyclization efficiency. **2012**, 3, 1489-1495		48
1010	Global analysis of small molecule binding to related protein targets. **2012**, 8, e1002333		35
1009	IspE inhibitors identified by a combination of in silico and in vitro high-throughput screening. **2012**, 7, e35792		15
1008	□Secretase Modulators: Can We Combine Potency with Safety?. **2012**, 2012, 295207		23
1007	Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties. **2012**, 18, 1292-1310		8
1006	Fragment library design considerations. **2012**, 2, 868-885		12
1005	Thermodynamics of fragment binding. *Journal of Chemical Information and Modeling*, **2012**, 52, 1039-45	6.1	55
1004	[1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. *Journal of Medicinal Chemistry*, **2012**, 55, 1127-36	8.3	62
1003	Fragment based drug discovery: practical implementation based on □□F NMR spectroscopy. *Journal of Medicinal Chemistry*, **2012**, 55, 678-87	8.3	65
1002	Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein. *Journal of Medicinal Chemistry*, **2012**, 55, 3261-73	8.3	76
1001	Fragment-Based Discovery of 7-Azabenzimidazoles as Potent, Highly Selective, and Orally Active CDK4/6 Inhibitors. *ACS Medicinal Chemistry Letters*, **2012**, 3, 445-9	4.3	27

1000	Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. *Journal of Medicinal Chemistry*, **2012**, 55, 587-96	8.3	158
999	Structural biology and drug discovery for protein-protein interactions. **2012**, 33, 241-8		130
998	Finding the sweet spot: the role of nature and nurture in medicinal chemistry. **2012**, 11, 355-65		295
997	Chapter 2:Thermodynamics of Ligand Binding. **2012**, 23-79		4
996	Chapter 7:Docking and Virtual Screening. **2012**, 171-194		
995	AtlasCBS: a web server to map and explore chemico-biological space. **2012**, 26, 995-1003		5
994	Analysis of structure-based virtual screening studies and characterization of identified active compounds. **2012**, 4, 603-13		35
993	Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design. *Journal of Medicinal Chemistry*, **2012**, 55, 9069-88	8.3	49
992	p21-Activated kinase inhibitors: a patent review. **2012**, 22, 293-310		36
991	Macrocycles in new drug discovery. **2012**, 4, 1409-38		284
990	Disease-Specific Differentiation Between Drugs and Non-Drugs Using Principal Component Analysis of Their Molecular Descriptor Space. **2012**, 31, 369-83		7
989	Discovery of selective LRRK2 inhibitors guided by computational analysis and molecular modeling. *Journal of Medicinal Chemistry*, **2012**, 55, 5536-45	8.3	62
988	Drug-like properties: guiding principles for the design of natural product libraries. **2012**, 75, 72-81		125
987	Biophysical limits of protein-ligand binding. *Journal of Chemical Information and Modeling*, **2012**, 52, 2098-106	3.1	31
986	Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. **2012**, 134, 11168-76		114
985	Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. *Journal of Medicinal Chemistry*, **2012**, 55, 7346-59	8.3	224
984	Identification of small-molecule antagonists of the Pseudomonas aeruginosa transcriptional regulator PqsR: biophysically guided hit discovery and optimization. *ACS Chemical Biology*, **2012**, 7, 1496-501	4.9	62
983	Fragment Deconstruction of Small, Potent Factor Xa Inhibitors: Exploring the Superadditivity Energetics of Fragment Linking in Protein−Ligand Complexes. **2012**, 124, 929-935		7

982	Experimental and computational active site mapping as a starting point to fragment-based lead discovery. **2012**, 7, 248-61		26
981	The development of FtsZ inhibitors as potential antibacterial agents. **2012**, 7, 1161-72		43
980	Computational fragment-based screening using RosettaLigand: the SAMPL3 challenge. **2012**, 26, 603-16		13
979	Structural characterization of inhibitors with selectivity against members of a homologous enzyme family. **2012**, 79, 128-36		16
978	The role of fragment-based and computational methods in polypharmacology. *Drug Discovery Today*, **2012**, 17, 23-34	8.8	95
977	Medicinal chemistry matters - a call for discipline in our discipline. *Drug Discovery Today*, **2012**, 17, 538-43	8.8	13
976	Molecular docking and enzymatic evaluation to identify selective inhibitors of aspartate semialdehyde dehydrogenase. **2012**, 20, 2950-6		9
975	Lead optimisation of pyrazoles as novel FPR1 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 532-6	2.9	10
974	Ligand based design of novel histamine H receptor antagonists; fragment optimization and analysis of binding kinetics. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 461-7	2.9	23
973	Synthesis of novel histamine H4 receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1156-9	2.9	11
972	The discovery of potent, selective, and orally active pyrazoloquinolines as PDE10A inhibitors for the treatment of Schizophrenia. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1019-22	2.9	26
971	Structure-based design, synthesis and structure-activity relationships of dibenzosuberyl- and benzoate-substituted tropines as ligands for acetylcholine-binding protein. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1448-54	2.9	2
970	New aromatase inhibitors from the 3-pyridyl arylether and 1-aryl pyrrolo[2,3-c]pyridine series. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 1860-3	2.9	10
969	SAR and biological evaluation of 3-azabicyclo[3.1.0]hexane derivatives as opioid ligands. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 2200-3	2.9	6
968	Synthesis of constrained benzocinnolinone analogues of CEP-26401 (irdabisant) as potent, selective histamine H3 receptor inverse agonists. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4198-202	2.9	5
967	Sulfonyl-morpholino-pyrimidines: SAR and development of a novel class of selective mTOR kinase inhibitor. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4163-8	2.9	25
966	Thieno[3,2-d]pyrimidin-4(3H)-one derivatives as PDK1 inhibitors discovered by fragment-based screening. *Bioorganic and Medicinal Chemistry Letters*, **2012**, 22, 4023-7	2.9	4
965	Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. **2012**, 7, 95-106		39

964	Identifizierung eines immunsuppressiven Wirkstoffmoleküls durch strukturbasiertes virtuelles Screening nach Inhibitoren von Protein-Protein-Wechselwirkungen. **2012**, 124, 264-268		7
963	Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. **2012**, 51, 258-61		31
962	Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. **2012**, 51, 905-11		41
961	Drug design for ever, from hype to hope. **2012**, 26, 137-50		29
960	Fragment informatics and computational fragment-based drug design: an overview and update. **2013**, 33, 554-98		36
959	Druggable chemical space and enumerative combinatorics. **2013**, 5, 19		9
958	Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. *Journal of Medicinal Chemistry*, **2013**, 56, 6495-511	8.3	86
957	1-Hydroxypyrazole as a bioisostere of the acetic acid moiety in a series of aldose reductase inhibitors. **2013**, 21, 4951-7		14
956	Fragment-based Drug Discovery: the Shape of Things to Come. **2013**, 66, 1544		2
955	Synthesis and evaluation of heteroaryl substituted diazaspirocycles as scaffolds to probe the ATP-binding site of protein kinases. **2013**, 21, 5707-24		15
954	Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 4571-8	2.9	17
953	Conversion Factors Among Various Ligand Efficiency Indices. **2013**, 157-158		
952	The AtlasCBS Application. **2013**, 49-62		
951	Navigating in Chemicobiological Space. **2013**, 91-105		
950	Progress towards water-soluble triazole-based selective MMP-2 inhibitors. **2013**, 11, 6623-41		25
949	A critical assessment of modeling safety-related drug attrition. **2013**, 4, 1058		33
948	Synthesis and on-target antibacterial activity of novel 3-elongated arylalkoxybenzamide derivatives as inhibitors of the bacterial cell division protein FtsZ. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 4076-9	2.9	10
947	Discovery and biophysical characterization of 2-amino-oxadiazoles as novel antagonists of PqsR, an important regulator of Pseudomonas aeruginosa virulence. *Journal of Medicinal Chemistry*, **2013**, 56, 6761-74	8.3	48

946	ClogP(alk): a method for predicting alkane/water partition coefficient. **2013**, 27, 389-402		22
945	Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. **2013**, 17, 320-8		53
944	Cyclopropane-based conformational restriction of GABA by a stereochemical diversity-oriented strategy: identification of an efficient lead for potent inhibitors of GABA transports. **2013**, 21, 4938-50		22
943	Steering target selectivity and potency by fragment-based de novo drug design. **2013**, 52, 10006-9		22
942	Crystallographic fragment screening and structure-based optimization yields a new class of influenza endonuclease inhibitors. *ACS Chemical Biology*, **2013**, 8, 2501-8	4.9	64
941	Identification of small-molecule binding pockets in the soluble monomeric form of the A□2 peptide. **2013**, 139, 035101		60
940	Design, synthesis and biological evaluation of a novel class of potent TGR5 agonists based on a 4-phenyl pyridine scaffold. **2013**, 69, 55-68		13
939	Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5980-91	2.9	133
938	Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases. *Journal of Medicinal Chemistry*, **2013**, 56, 7049-59	8.3	23
937	Lead identification of novel and selective TYK2 inhibitors. **2013**, 67, 175-87		61
936	Protein-protein interactions as druggable targets: recent technological advances. **2013**, 13, 791-6		94
935	2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5014-21	2.9	30
934	Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5923-30	2.9	12
933	Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy. *ACS Medicinal Chemistry Letters*, **2013**, 4, 948-52	4.3	15
932	The development of CNS-active LRRK2 inhibitors using property-directed optimisation. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3690-6	2.9	21
931	Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6172-7	2.9	76
930	The thermodynamic basis for the use of lipophilic efficiency (LipE) in enthalpic optimizations. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5992-6000	2.9	74
929	Exploring the binding of peptidic West Nile virus NS2B-NS3 protease inhibitors by NMR. **2013**, 97, 137-44		28

928	New synthesis and tritium labeling of a selective ligand for studying high-affinity -hydroxybutyrate (GHB) binding sites. *Journal of Medicinal Chemistry*, **2013**, 56, 8201-5	8.3	20
927	Fragment Screening on Staphylococcus aureus HPPK a Folate Pathway Target. **2013**, 66, 1537		4
926	Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5533-9	2.9	45
925	Fragment-based discovery of 6-azaindazoles as inhibitors of bacterial DNA ligase. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1208-12	4.3	19
924	Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor. **2013**, 21, 5081-97		14
923	Structure-based ligand discovery targeting orthosteric and allosteric pockets of dopamine receptors. **2013**, 84, 794-807		69
922	Fragment-based discovery of focal adhesion kinase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 5401-9	2.9	19
921	Comprehending renin inhibitor's binding affinity using structure-based approaches. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6667-72	2.9	3
920	De Novo Design: From Models to Molecules. **2013**, 1-55		9
919	Hit and Lead Identification from Fragments. **2013**, 143-200		1
918	Design, synthesis, and biological evaluation of potent and selective class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. *Journal of Medicinal Chemistry*, **2013**, 56, 9934-54	8.3	96
917	Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1). *Journal of Medicinal Chemistry*, **2013**, 56, 10045-65	8.3	57
916	A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors. **2013**, 5, 2019-35		19
915	Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. *Journal of Medicinal Chemistry*, **2013**, 56, 982-92	8.3	41
914	Discovery of a potent inhibitor of replication protein a protein-protein interactions using a fragment-linking approach. *Journal of Medicinal Chemistry*, **2013**, 56, 9242-50	8.3	48
913	Discovery of 2 Adrenergic Receptor Ligands Using Biosensor Fragment Screening of Tagged Wild-Type Receptor. *ACS Medicinal Chemistry Letters*, **2013**, 4, 1005-1010	4.3	55
912	Complementarity between in silico and biophysical screening approaches in fragment-based lead discovery against the A(2A) adenosine receptor. *Journal of Chemical Information and Modeling*, **2013**, 53, 2701-14	6.1	55
911	Training based on ligand efficiency improves prediction of bioactivities of ligands and drug target proteins in a machine learning approach. *Journal of Chemical Information and Modeling*, **2013**, 53, 2525-37	6.1	15

910	Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptor. *Journal of Medicinal Chemistry*, **2013**, 56, 7243-59	8.3	18
909	Discovery of biological evaluation of pyrazole/imidazole amides as mGlu5 receptor negative allosteric modulators. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 2134-9	2.9	21
908	Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia. *Journal of Medicinal Chemistry*, **2013**, 56, 7590-607	8.3	75
907	Glossary of Terms Used in Medicinal Chemistry Part II (IUPAC Recommendations 2013). **2013**, 48, 387-418		1
906	Serendipity in drug-discovery: a new series of 2-(benzyloxy)benzamides as TRPM8 antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6118-22	2.9	10
905	Screening efficient BH3-mimetics to hBcl-B by means of peptidodynmimetic method. **2013**, 9, 700-12		7
904	Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads. **2013**, 52, 4676-81		20
903	Using a fragment-based approach to target protein-protein interactions. **2013**, 14, 332-42		99
902	. **2013**,		
901	Optimisation of biphenyl acetic acid inhibitors of diacylglycerol acetyl transferase 1 the discovery of AZD2353. **2013**, 4, 159-164		7
900	Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries. *Journal of Chemical Information and Modeling*, **2013**, 53, 534-44	6.1	20
899	Design, synthesis, and binding mode prediction of 2-pyridone-based selective CB2 receptor agonists. **2013**, 21, 2045-55		26
898	Fragment-based design, synthesis, and biological evaluation of N-substituted-5-(4-isopropylthiophenol)-2-hydroxynicotinamide derivatives as novel Mcl-1 inhibitors. **2013**, 60, 410-20		20
897	Computational modeling and design of renin inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 460-5	2.9	1
896	Design and synthesis of diazatricyclodecane agonists of the G-protein-coupled receptor 119. *Journal of Medicinal Chemistry*, **2013**, 56, 301-19	8.3	27
895	Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(N-arylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease. *Journal of Medicinal Chemistry*, **2013**, 56, 534-46	8.3	130
894	Inflation of correlation in the pursuit of drug-likeness. **2013**, 27, 1-13		60
893	S4MPLE--sampler for multiple protein-ligand entities: simultaneous docking of several entities. *Journal of Chemical Information and Modeling*, **2013**, 53, 88-102	6.1	20

892	Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. *Journal of Medicinal Chemistry*, **2013**, 56, 2270-82	8.3	36
891	Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. *Journal of Medicinal Chemistry*, **2013**, 56, 1878-93	8.3	28
890	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif. *Journal of Medicinal Chemistry*, **2013**, 56, 1772-6	8.3	81
889	A chemogenomic analysis of ionization constants--implications for drug discovery. **2013**, 8, 242-55		32
888	Discovery of Schaeffer's acid analogues as lead structures of mycobacterium tuberculosis type II dehydroquinase using a rational drug design approach. **2013**, 8, 54-8		9
887	Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6239-42	2.9	9
886	Imidazopyridazines as potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1): Preparation and evaluation of pyrazole linked analogues. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 6019-24	2.9	28
885	Aromatic glycosyl disulfide derivatives: evaluation of their inhibitory activities against Trypanosoma cruzi. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3576-9	2.9	14
884	Investigation of the influence of molecular topology on ligand binding. **2013**, 40, 22-9		0
883	1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling. **2013**, 49, 423-33		13
882	Large-scale prediction of human kinase-inhibitor interactions using protein sequences and molecular topological structures. **2013**, 792, 10-8		20
881	Identification of novel D-amino acid oxidase inhibitors by in silico screening and their functional characterization in vitro. *Journal of Medicinal Chemistry*, **2013**, 56, 1894-907	8.3	33
880	Detecting allosteric sites of HIV-1 reverse transcriptase by X-ray crystallographic fragment screening. *Journal of Medicinal Chemistry*, **2013**, 56, 2738-46	8.3	64
879	Antitrypanosomal lead discovery: identification of a ligand-efficient inhibitor of Trypanosoma cruzi CYP51 and parasite growth. *Journal of Medicinal Chemistry*, **2013**, 56, 2556-67	8.3	54
878	Fragment-based drug discovery using a multidomain, parallel MD-MM/PBSA screening protocol. *Journal of Chemical Information and Modeling*, **2013**, 53, 560-72	6.1	16
877	From heptahelical bundle to hits from the Haystack: structure-based virtual screening for GPCR ligands. **2013**, 522, 279-336		44
876	Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity. *Journal of Medicinal Chemistry*, **2013**, 56, 2125-38	8.3	158
875	Design of libraries targeting protein-protein interfaces. **2013**, 8, 726-32		29

874	De novo fragment design: a medicinal chemistry approach to fragment-based lead generation. *Journal of Medicinal Chemistry*, **2013**, 56, 3115-9	8.3	26
873	Structure-based target druggability assessment. **2013**, 986, 141-64		14
872	Biophysical fragment screening of the 1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. *Journal of Medicinal Chemistry*, **2013**, 56, 3446-55	8.3	129
871	In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE. *Journal of Chemical Information and Modeling*, **2013**, 53, 836-51	6.1	28
870	Rational design of small-molecule inhibitors for catenin/T-cell factor protein-protein interactions by bioisostere replacement. *ACS Chemical Biology*, **2013**, 8, 524-9	4.9	39
869	Artemisinin-polypyrrole conjugates: synthesis, DNA binding studies and preliminary antiproliferative evaluation. **2013**, 8, 709-18		6
868	Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 Diabetes. *ACS Medicinal Chemistry Letters*, **2013**, 4, 441-445	4.3	50
867	Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis. *Journal of Medicinal Chemistry*, **2013**, 56, 3820-32	8.3	57
866	Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. *Drug Discovery Today*, **2013**, 18, 323-30	8.8	26
865	Discovery of novel pyrazolo[1,5-a]pyrimidines as potent pan-Pim inhibitors by structure- and property-based drug design. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3149-53	2.9	44
864	Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control. *Journal of Medicinal Chemistry*, **2013**, 56, 3922-35	8.3	47
863	De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments. *ACS Chemical Biology*, **2013**, 8, 1044-52	4.9	39
862	Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125). *Journal of Medicinal Chemistry*, **2013**, 56, 4343-56	8.3	30
861	Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonist. *Journal of Medicinal Chemistry*, **2013**, 56, 4899-911	8.3	31
860	Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery. **2013**, 5, e201302011		135
859	Novel soluble myeloid cell leukemia sequence 1 (Mcl-1) inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g) developed using a fragment-based approach. **2013**, 59, 141-9		23
858	Hydration properties of ligands and drugs in protein binding sites: tightly-bound, bridging water molecules and their effects and consequences on molecular design strategies. *Journal of Chemical Information and Modeling*, **2013**, 53, 1388-405	6.1	53
857	Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, part I: transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 3438-42	2.9	16

856	Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. *Journal of Medicinal Chemistry*, **2013**, 56, 6560-72	8.3	141
855	Front Matter. **2013**, I-XXVIII		
854	Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors. *Journal of Chemical Information and Modeling*, **2013**, 53, 1100-12	6.1	26
853	Fragment-based drug discovery using NMR spectroscopy. **2013**, 56, 65-75		147
852	Quinolin-4(1H)-imines are potent antiplasmodial drugs targeting the liver stage of malaria. *Journal of Medicinal Chemistry*, **2013**, 56, 4811-5	8.3	18
851	Deconstruction of a nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor. *ACS Medicinal Chemistry Letters*, **2013**, 4, 660-5	4.3	46
850	Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2. *Journal of Medicinal Chemistry*, **2013**, 56, 4764-85	8.3	48
849	Fragment screening by weak affinity chromatography: comparison with established techniques for screening against HSP90. **2013**, 85, 6756-66		48
848	Inhibitors of HIV-1 attachment. Part 8: the effect of C7-heteroaryl substitution on the potency, and in vitro and in vivo profiles of indole-based inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 203-8	2.9	32
847	Development of a plate-based optical biosensor fragment screening methodology to identify phosphodiesterase 10A inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 3228-34	8.3	17
846	Prospective use of molecular field points in ligand-based virtual screening: efficient identification of new reversible Cdc25 inhibitors. **2013**, 4, 1148		5
845	Optimization of O3-acyl kojic acid derivatives as potent and selective human neutrophil elastase inhibitors. *Journal of Medicinal Chemistry*, **2013**, 56, 9802-6	8.3	20
844	Flavones as isosteres of 4(1H)-quinolones: discovery of ligand efficient and dual stage antimalarial lead compounds. **2013**, 69, 872-80		11
843	Design, synthesis and discovery of picomolar selective α7 nicotinic acetylcholine receptor ligands. *Journal of Medicinal Chemistry*, **2013**, 56, 8404-21	8.3	15
842	Discovery of an allosteric inhibitor binding site in 3-Oxo-acyl-ACP reductase from Pseudomonas aeruginosa. *ACS Chemical Biology*, **2013**, 8, 2518-27	4.9	26
841	The significance of acid/base properties in drug discovery. **2013**, 42, 485-96		181
840	Stabilised G protein-coupled receptors in structure-based drug design: a case study with adenosine A2A receptor. **2013**, 4, 52-67		23
839	Small-molecule inhibitors of human LDH5. **2013**, 5, 1967-91		53

838	Computational fragment-based drug design. **2013**, 22-32		
837	Non-peptidic cruzain inhibitors with trypanocidal activity discovered by virtual screening and in vitro assay. **2013**, 7, e2370		54
836	Glossary of terms used in medicinal chemistry. Part II (IUPAC Recommendations 2013). **2013**, 85, 1725-1758		10
835	A Crowd-Based Process and Tool for HTS Hit Triage. **2013**, 32, 337-45		4
834	In silico optimization of a fragment-based hit yields biologically active, high-efficiency inhibitors for glutamate racemase. **2013**, 8, 1681-9		9
833	From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules. **2013**, 8, 1127-37		24
832	Drugs, non-drugs, and disease category specificity: organ effects by ligand pharmacology. **2013**, 24, 319-31		8
831	Wirkstoffe nach Zahlen: reaktionsbasierter De-novo-Entwurf von potenten und selektiven Leitstrukturen f□ die Krebsforschung. **2013**, 125, 4774-4779		9
830	4-Acyl Pyrroles: Mimicking Acetylated Lysines in Histone Code Reading. **2013**, 125, 14305-14309		6
829	Steering Target Selectivity and Potency by Fragment-Based De Novo Drug Design. **2013**, 125, 10190-10193		7
828	4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. **2013**, 52, 14055-9		90
827	Genome-scale screening of drug-target associations relevant to Ki using a chemogenomics approach. **2013**, 8, e57680		27
826	Anti-aggregating effect of the naturally occurring dipeptide carnosine on a□-42 fibril formation. **2013**, 8, e68159		45
825	Structure-and-mechanism-based design and discovery of type II Mycobacterium tuberculosis dehydroquinate dehydratase inhibitors. **2014**, 14, 51-63		4
824	Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors. *Molecules*, **2013**, 18, 13487-509	4.8	3
823	Peptide-ligand binding modeling of siRNA with cell-penetrating peptides. **2014**, 2014, 257040		7
822	Drug-likeness approach of 2-aminopyrimidines as histamine H3 receptor ligands. **2014**, 8, 1499-513		10
821	. **2014**,		20

820	. **2014**,		36
819	Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. **2014**, 6, 179-204		27
818	Structural Biology and Anticancer Drug Design. **2014**, 121-141		1
817	Composing compound libraries for hit discovery--rationality-driven preselection or random choice by structural diversity?. **2014**, 6, 2057-72		14
816	Activity-limiting role of molecular size: size-dependency of maximum activity for P450 inhibition as revealed by qHTS data. **2014**, 42, 1785-90		6
815	Fragment screening by SPR and advanced application to GPCRs. **2014**, 116, 113-23		55
814	The Drug Discovery Process. **2014**, 281-320		2
813	Advances in multiparameter optimization methods for de novo drug design. **2014**, 9, 803-17		46
812	The ChEMBL bioactivity database: an update. **2014**, 42, D1083-90		1052
811	Chemical, target, and bioactive properties of allosteric modulation. **2014**, 10, e1003559		63
810	Identification and characterization of hundreds of potent and selective inhibitors of Trypanosoma brucei growth from a kinase-targeted library screening campaign. **2014**, 8, e3253		45
809	The discovery of aurora kinase inhibitor by multi-docking-based virtual screening. *International Journal of Molecular Sciences*, **2014**, 15, 20403-12	6.3	2
808	Small-Molecule Library Subset Screening as an Aid for Accelerating Lead Identification. **2014**, 19, 758-70		14
807	The ChEMBL database: a taster for medicinal chemists. **2014**, 6, 361-4		32
806	Alternative variables in drug discovery: promises and challenges. **2014**, 6, 577-93		11
805	Selective JAK inhibitors. **2014**, 6, 1439-71		28
804	Identification of Novel Histamine H4 Ligands by Virtual Screening on Molecular Dynamics Ensembles. **2014**, 33, 264-8		7
803	Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5704-5709	2.9	12

802	Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 5683-5687	2.9	17
801	Fragment-based approaches to the discovery of kinase inhibitors. **2014**, 548, 69-92		9
800	Structure-based drug design for G protein-coupled receptors. *Progress in Medicinal Chemistry*, **2014**, 53, 1-63	7.3	57
799	From three-dimensional GPCR structure to rational ligand discovery. **2014**, 796, 129-57		26
798	Computational and experimental prediction of human C-type lectin receptor druggability. **2014**, 5, 323		37
797	Novel 9-(alkylthio)-Acenaphtho[1,2-e]-1,2,4-triazine derivatives: synthesis, cytotoxic activity and molecular docking studies on B-cell lymphoma 2 (Bcl-2). **2014**, 22, 2		12
796	N-Myristoyltransferase as a potential drug target in malaria and leishmaniasis. **2014**, 141, 37-49		55
795	A cautionary tale of structure-guided inhibitor development against an essential enzyme in the aspartate-biosynthetic pathway. **2014**, 70, 3244-52		6
794	Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 954-62	2.9	12
793	Exploring unsymmetrical dyads as efficient inhibitors against the insect β-N-acetyl-D-hexosaminidase OfHex2. **2014**, 97, 152-62		8
792	Biofragments: an approach towards predicting protein function using biologically related fragments and its application to Mycobacterium tuberculosis CYP126. **2014**, 15, 549-55		6
791	Discovery of innovative therapeutics: today's realities and tomorrow's vision. 2. Pharma's challenges and their commitment to innovation. *Journal of Medicinal Chemistry*, **2014**, 57, 5525-53	8.3	34
790	Formation of activity cliffs is accompanied by systematic increases in ligand efficiency from lowly to highly potent compounds. **2014**, 16, 335-41		4
789	Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography. **2014**, 22, 2427-34		30
788	Decreasing acidity in a series of aldose reductase inhibitors: 2-Fluoro-4-(1H-pyrrol-1-yl)phenol as a scaffold for improved membrane permeation. **2014**, 22, 2194-207		15
787	Hot spot-based design of small-molecule inhibitors for protein-protein interactions. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2546-54	2.9	106
786	Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity. **2014**, 59, 69-82		17
785	Structure-activity study leading to identification of a highly active thienopyrimidine based EGFR inhibitor. **2014**, 75, 354-74		46

784	Multiparameter Optimization of ADMET for Drug Design. **2014**, 145-166		1
783	Validity of ligand efficiency metrics. *ACS Medicinal Chemistry Letters*, **2014**, 5, 616-8	4.3	85
782	"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets. **2014**, 10, 1998-2022		24
781	Fragment-based lead discovery and design. *Journal of Chemical Information and Modeling*, **2014**, 54, 693-704	4.1	96
780	Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. *Journal of Medicinal Chemistry*, **2014**, 57, 1276-88	8.3	90
779	Begin with the End in Mind. **2014**, 231-245		
778	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction. **2014**, 81, 277-88		25
777	Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 2493-6	2.9	53
776	Design and synthesis of high affinity inhibitors of Plasmodium falciparum and Plasmodium vivax N-myristoyltransferases directed by ligand efficiency dependent lipophilicity (LELP). *Journal of Medicinal Chemistry*, **2014**, 57, 2773-88	8.3	52
775	Physical Properties in Drug Design. **2014**, 1-68		9
774	G Protein-Coupled Receptors - Modeling and Simulation. **2014**,		7
773	Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT). *Journal of Medicinal Chemistry*, **2014**, 57, 770-92	8.3	28
772	Structure-based drug design of chromone antagonists of the adenosine A2A receptor. **2014**, 5, 571-575		22
771	The role of ligand efficiency metrics in drug discovery. **2014**, 13, 105-21		649
770	Data-driven medicinal chemistry in the era of big data. *Drug Discovery Today*, **2014**, 19, 859-68	8.8	101
769	Discovery of a benzimidazole series of ADAMTS-5 (aggrecanase-2) inhibitors by scaffold hopping. **2014**, 71, 250-8		13
768	Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 731-6	2.9	11
767	Improving the plausibility of success with inefficient metrics. *ACS Medicinal Chemistry Letters*, **2014**, 5, 2-5	4.3	48

766	Biased multicomponent reactions to develop novel bromodomain inhibitors. *Journal of Medicinal Chemistry*, **2014**, 57, 9019-27	8.3	67
765	Studies on molecular properties prediction and histamine H3 receptor affinities of novel ligands with uracil-based motifs. **2014**, 86, 578-88		9
764	Advancing the Drug Discovery and Development Process. **2014**, 126, 9280-9292		16
763	Identification of novel inhibitors of human Chk1 using pharmacophore-based virtual screening and their evaluation as potential anti-cancer agents. **2014**, 28, 1247-56		8
762	Novel tactics for designing water-soluble molecules in drug discovery. **2014**, 9, 1421-33		32
761	Portraying G protein-coupled receptors with fluorescent ligands. *ACS Chemical Biology*, **2014**, 9, 1918-284.9		24
760	Lead Discovery and Lead Modification. **2014**, 19-122		5
759	Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening. **2014**, 22, 6409-21		25
758	The essential roles of chemistry in high-throughput screening triage. **2014**, 6, 1265-90		93
757	Identification of orally bioavailable small-molecule inhibitors of hematopoietic prostaglandin D2 synthase using X-ray fragment based drug discovery. **2014**, 5, 134-141		8
756	n-Alkylboronic acid inhibitors reveal determinants of ligand specificity in the quorum-quenching and siderophore biosynthetic enzyme PvdQ. **2014**, 53, 6679-86		13
755	Recent advances in the structure-based rational design of TNKSIs. **2014**, 10, 2783-99		18
754	The fight against the influenza A virus H1N1: synthesis, molecular modeling, and biological evaluation of benzofurazan derivatives as viral RNA polymerase inhibitors. **2014**, 9, 129-50		24
753	Improving the use of ranking in virtual screening against HIV-1 integrase with triangular numbers and including ligand profiling with antitargets. *Journal of Chemical Information and Modeling*, **2014**, 54, 3172-85	6.1	10
752	Computational prediction and validation of an expert's evaluation of chemical probes. *Journal of Chemical Information and Modeling*, **2014**, 54, 2996-3004	6.1	20
751	How proteins bind macrocycles. **2014**, 10, 723-31		266
750	Cyclic secondary sulfonamides: unusually good inhibitors of cancer-related carbonic anhydrase enzymes. *Journal of Medicinal Chemistry*, **2014**, 57, 3522-31	8.3	74
749	Stereoselective construction of the 5-hydroxy diazabicyclo[4.3.1]decane-2-one scaffold, a privileged motif for FK506-binding proteins. **2014**, 16, 5254-7		23

748	Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4546-4552	2.9	19
747	Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry. **2014**, 9-28		
746	Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. **2014**, 136, 9308-19		198
745	Design, synthesis, and local anti-inflammatory activity of 17-carboxamide derivatives of glucocorticoids. **2014**, 347, 786-97		6
744	Thieno[2,3-b]pyridines as negative allosteric modulators of metabotropic GluR5 receptors: hit-to-lead optimization. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 3845-9	2.9	6
743	High-affinity small-molecule inhibitors of the menin-mixed lineage leukemia (MLL) interaction closely mimic a natural protein-protein interaction. *Journal of Medicinal Chemistry*, **2014**, 57, 1543-56	8.3	69
742	Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator. *Journal of Medicinal Chemistry*, **2014**, 57, 861-77	8.3	45
741	Off-rate screening (ORS) by surface plasmon resonance. An efficient method to kinetically sample hit to lead chemical space from unpurified reaction products. *Journal of Medicinal Chemistry*, **2014**, 57, 2845-50	8.3	39
740	Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: Novel 2-amidinophenylbenzamides as potent inhibitors of venezuelan equine encephalitis virus. *Journal of Medicinal Chemistry*, **2014**, 57, 8608-21	8.3	33
739	Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists. *ACS Medicinal Chemistry Letters*, **2014**, 5, 1114-8	4.3	24
738	Cytotoxic activity assessment and c-Src tyrosine kinase docking simulation of thieno[2,3-b] pyridine-based derivatives. **2014**, 23, 1225-1233		6
737	Advancing the drug discovery and development process. **2014**, 53, 9128-40		53
736	In silico investigation of medicinal spectrum of imidazo-azines from the perspective of multitarget screening against malaria, tuberculosis and Chagas disease. **2014**, 50, 1-9		8
735	Indazole- and indole-5-carboxamides: selective and reversible monoamine oxidase B inhibitors with subnanomolar potency. *Journal of Medicinal Chemistry*, **2014**, 57, 6679-703	8.3	61
734	Discovery of selective ligands for telomeric RNA G-quadruplexes (TERRA) through 19F-NMR based fragment screening. *ACS Chemical Biology*, **2014**, 9, 1559-66	4.9	50
733	Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. *Journal of Medicinal Chemistry*, **2014**, 57, 4876-88	8.3	50
732	Increasing chemical space coverage by combining empirical and computational fragment screens. *ACS Chemical Biology*, **2014**, 9, 1528-35	4.9	40
731	Modern Cancer Drug Discovery. **2014**, 3-53		5

730	Discovery of novel non-carboxylic acid 5-amino-4-cyanopyrazole derivatives as potent and highly selective LPA1R antagonists. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 4450-4454	2.9	11
729	Discovery and optimization of pyrimidone indoline amide PI3K□nhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers. *Journal of Medicinal Chemistry*, **2014**, 57, 903-20	8.3	64
728	Targeting dynamic pockets of HIV-1 protease by structure-based computational screening for allosteric inhibitors. *Journal of Chemical Information and Modeling*, **2014**, 54, 987-91	6.1	23
727	Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series. *Bioorganic and Medicinal Chemistry Letters*, **2014**, 24, 1681-4	2.9	21
726	Fragment screening reveals salicylic hydroxamic acid as an inhibitor of Trypanosoma brucei GPI GlcNAc-PI de-N-acetylase. **2014**, 387, 54-8		10
725	Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery. **2014**, 106, 61-70		47
724	Ligand efficiency metrics considered harmful. **2014**, 28, 699-710		45
723	Halogen-enriched fragment libraries as chemical probes for harnessing halogen bonding in fragment-based lead discovery. **2014**, 6, 617-39		30
722	Synthesis, biological evaluation, and structure-activity relationships of potent noncovalent and nonpeptidic cruzain inhibitors as anti-Trypanosoma cruzi agents. *Journal of Medicinal Chemistry*, **2014**, 57, 2380-92	8.3	44
721	Ligand efficiency based approach for efficient virtual screening of compound libraries. **2014**, 83, 226-35		10
720	Advances in the Understanding of Drug Properties in Medicinal Chemistry. **2015**, 305-322		1
719	Computational Techniques to Support Hit Triage. **2015**, 189-220		3
718	One Crystal, Two Temperatures: Cryocooling Penalties Alter Ligand Binding to Transient Protein Sites. **2015**, 16, 1560-4		51
717	Development of Small-Molecule Trypanosoma brucei N-Myristoyltransferase Inhibitors: Discovery and Optimisation of a Novel Binding Mode. **2015**, 10, 1821-36		17
716	Thermodynamics-Guided Optimizations in Medicinal Chemistry. **2015**, 63-80		
715	Designing CNS Drugs for Optimal Brain Exposure. **2015**, 385-424		2
714	- Ligand-Based Drug Discovery and Design. **2015**, 116-139		2
713	Rational Design of Highly Potent and Slow-Binding Cytochrome bc1 Inhibitor as Fungicide by Computational Substitution Optimization. **2015**, 5,		14

712	Challenges in the Medicinal Chemical Optimization of Binding Kinetics. **2015**, 191-210		
711	Protein X-Ray Crystallography in Structure-Based Drug Design. **2015**, 183-198		
710	Ligand Efficiency Outperforms pIC50 on Both 2D MLR and 3D CoMFA Models: A Case Study on AR Antagonists. **2015**, 86, 1501-17		5
709	De-novo-Fragmententwurf f□ die Wirkstoffforschung und chemische Biologie. **2015**, 127, 15294-15298		5
708	De Novo Fragment Design for Drug Discovery and Chemical Biology. **2015**, 54, 15079-83		25
707	Synthesis and Pharmacological Evaluation of □2 Nicotinic Ligands with a 3-Fluoropyrrolidine Nucleus. **2015**, 10, 1071-8		1
706	Discovery of a novel general anesthetic chemotype using high-throughput screening. **2015**, 122, 325-33		14
705	Charting a Path to Success in Virtual Screening. *Molecules*, **2015**, 20, 18732-58	4.8	52
704	[Fragment-based screening: a promising avenue for drug design]. **2015**, 31, 197-202		0
703	. **2015**,		6
702	. **2015**,		5
701	. **2015**,		17
700	. **2015**,		5
699	Editorial: medicinal chemistry studies of neglected diseases. **2015**, 15, 180-1		
698	Identification of indole inhibitors of human hematopoietic prostaglandin D2 synthase (hH-PGDS). *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 2496-500	2.9	9
697	Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. *Journal of Medicinal Chemistry*, **2015**, 58, 5053-74	8.3	8
696	Fragment-Based Discovery of Potent and Selective DDR1/2 Inhibitors. *ACS Medicinal Chemistry Letters*, **2015**, 6, 798-803	4.3	37
695	Small-Molecule Modulation of Methyl-Lysine-Mediated Interactions. **2015**, 243-271		2

694	Molecular Obesity, Potency and Other Addictions in Drug Discovery. **2015**, 183-196		2
693	Probing the pharmacology of G protein-coupled receptors with fluorescent ligands. **2015**, 98, 48-57		49
692	Exploring S1 plasticity and probing S1' subsite of mammalian aminopeptidase N/CD13 with highly potent and selective aminobenzosuberone inhibitors. **2015**, 23, 3192-207		7
691	Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening. **2015**, 112, 6979-84		13
690	Perspective: Tyrosine phosphatases as novel targets for antiplatelet therapy. **2015**, 23, 2786-97		21
689	Design of pyrazolo-pyrimidines as 11β-HSD1 inhibitors through optimisation of molecular electrostatic potential. **2015**, 6, 926-934		3
688	Cell-Based Selection Expands the Utility of DNA-Encoded Small-Molecule Library Technology to Cell Surface Drug Targets: Identification of Novel Antagonists of the NK3 Tachykinin Receptor. **2015**, 17, 722-31		85
687	DOCKTITE-a highly versatile step-by-step workflow for covalent docking and virtual screening in the molecular operating environment. *Journal of Chemical Information and Modeling*, **2015**, 55, 398-406	6.1	84
686	A new paradigm for known metabolite identification in metabonomics/metabolomics: metabolite identification efficiency. **2015**, 13, 131-44		36
685	Iminopyrimidinones: a novel pharmacophore for the development of orally active renin inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1592-6	2.9	4
684	Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer's disease. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1086-91	2.9	22
683	Design and synthesis of N-hydroxytriazole-4-carboxamides as HIV integrase inhibitors. **2015**, 24, 423-429		2
682	Discovery of AZD3147: a potent, selective dual inhibitor of mTORC1 and mTORC2. *Journal of Medicinal Chemistry*, **2015**, 58, 2326-49	8.3	20
681	Molecular recognition in chemical and biological systems. **2015**, 54, 3290-327		380
680	Ac-tLeu-Asp-H is the minimal and highly effective human caspase-3 inhibitor: biological and in silico studies. **2015**, 47, 153-62		3
679	Applying thermodynamic profiling in lead finding and optimization. **2015**, 14, 95-110		202
678	Structure-Based Design, Synthesis by Click Chemistry and Activity of Highly Selective A Adenosine Receptor Agonists. **2015**, 6, 555-563		16
677	Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold. *Journal of Medicinal Chemistry*, **2015**, 58, 1205-14	8.3	64

676	Identification of novel aminothiazole and aminothiadiazole conjugated cyanopyridines as selective CHK1 inhibitors. **2015**, 92, 459-70		14
675	A desirability function-based scoring scheme for selecting fragment-like class A aminergic GPCR ligands. **2015**, 29, 59-66		6
674	Novel pyrrole derivatives as selective CHK1 inhibitors: design, regioselective synthesis and molecular modeling. **2015**, 6, 852-859		9
673	Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold. *Journal of Medicinal Chemistry*, **2015**, 58, 2649-57	8.3	27
672	Multifaceted Roles of Crystallography in Modern Drug Discovery. **2015**,		1
671	Molekulare Erkennung in chemischen und biologischen Systemen. **2015**, 127, 3341-3382		95
670	Fragment-Based Methods in Drug Discovery. **2015**,		3
669	Fragment-based design of kinase inhibitors: a practical guide. **2015**, 1289, 157-83		3
668	Fragment-Based Discovery of a Small Molecule Inhibitor of Bruton's Tyrosine Kinase. *Journal of Medicinal Chemistry*, **2015**, 58, 5437-44	8.3	46
667	Overcoming Chemical, Biological, and Computational Challenges in the Development of Inhibitors Targeting Protein-Protein Interactions. **2015**, 22, 689-703		103
666	Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists. **2015**, 101, 681-91		24
665	Optimization of 3-aryl-3-ethoxypropanoic acids and discovery of the potent GPR40 agonist DS-1558. **2015**, 23, 5546-65		14
664	Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Discovery of a Non-Alanine Lead Series with Dual Activity Against cIAP1 and XIAP. *Journal of Medicinal Chemistry*, **2015**, 58, 6574-88	8.3	67
663	Identification and structure solution of fragment hits against kinetoplastid N-myristoyltransferase. **2015**, 71, 586-93		
662	In Silico Screening. **2015**, 141-160		0
661	Compound Properties and their Influence on Drug Quality. **2015**, 379-393		5
660	Protein Crystallography and Drug Discovery. **2015**, 511-537		3
659	Emerging Epigenetic TherapiesBromodomain Ligands. **2015**, 495-524		1

658	Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling. **2015**, 61, 61-84		3
657	Discovery and Structure Enabled Synthesis of 2,6-Diaminopyrimidin-4-one IRAK4 Inhibitors. *ACS Medicinal Chemistry Letters*, **2015**, 6, 942-7	4.3	17
656	Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 3203-7	2.9	9
655	The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS Hits. *Journal of Medicinal Chemistry*, **2015**, 58, 7140-63	8.3	22
654	Cell-based and virtual fragment screening for adrenergic β2C receptor agonists. **2015**, 23, 3991-9		10
653	Identification of protein kinase CK2 inhibitors using solvent dipole ordering virtual screening. **2015**, 96, 396-404		12
652	Target specific proteochemometric model development for BACE1 - protein flexibility and structural water are critical in virtual screening. **2015**, 11, 1955-72		17
651	Discovery and hit-to-lead optimization of 2,6-diaminopyrimidine inhibitors of interleukin-1 receptor-associated kinase 4. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 1836-41	2.9	16
650	Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 9421-37	8.3	161
649	Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. *Journal of Medicinal Chemistry*, **2015**, 58, 4790-801	8.3	63
648	Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 2461-8	2.9	25
647	Combining label-free cell phenotypic profiling with computational approaches for novel drug discovery. **2015**, 10, 331-43		17
646	Identification of the molecular basis of inhibitor selectivity between the human and streptococcal type I methionine aminopeptidases. *Journal of Medicinal Chemistry*, **2015**, 58, 2350-7	8.3	14
645	Dopamine D1 receptor-agonist interactions: A mutagenesis and homology modeling study. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 2106-11	2.9	10
644	How many molecules does it take to tell a story? Case studies, language, and an epistemic view of medicinal chemistry. **2015**, 10, 949-56		12
643	Discovery of Potent Inhibitors of Schistosoma mansoni NAD+ Catabolizing Enzyme. *Journal of Medicinal Chemistry*, **2015**, 58, 3582-92	8.3	12
642	Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis. *Journal of Medicinal Chemistry*, **2015**, 58, 7888-94	8.3	37
641	Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. **2015**, 23, 6666-72		28

640	Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity. **2015**, 23, 7000-6		15
639	Lessons from Hot Spot Analysis for Fragment-Based Drug Discovery. **2015**, 36, 724-736		42
638	pROC-Chemotype Plots Enhance the Interpretability of Benchmarking Results in Structure-Based Virtual Screening. *Journal of Chemical Information and Modeling*, **2015**, 55, 2297-307	6.1	16
637	Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). *Journal of Medicinal Chemistry*, **2015**, 58, 6653-64	8.3	126
636	Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 5258-64	2.9	17
635	Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase for the Treatment of Respiratory Disease. *Journal of Medicinal Chemistry*, **2015**, 58, 7381-99	8.3	93
634	Quantum Corrections to the Free Energy Difference between Peptides and Proteins Conformers. **2015**, 11, 4011-22		4
633	A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis. *ACS Infectious Diseases*, **2015**, 1, 604-14	5.5	17
632	Steering the azido-tetrazole equilibrium of 4-azidopyrimidines via substituent variation - implications for drug design and azide-alkyne cycloadditions. **2015**, 13, 10620-30		13
631	Probing the structural requirements of non-electrophilic naphthalene-based Nrf2 activators. **2015**, 103, 252-68		63
630	Fragment-based discovery of potent ERK2 pyrrolopyrazine inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 4728-4732	2.9	9
629	Phenylalanine and Phenylglycine Analogues as Arginine Mimetics in Dengue Protease Inhibitors. *Journal of Medicinal Chemistry*, **2015**, 58, 7719-33	8.3	53
628	Ligand efficiency metrics: why all the fuss?. **2015**, 7, 1363-5		19
627	The impact of binding thermodynamics on medicinal chemistry optimizations. **2015**, 7, 1285-303		7
626	Kinetic binding assays for the analysis of protein-ligand interactions. **2015**, 17, 1-8		15
625	Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists. **2015**, 23, 7158-64		20
624	On-rate based optimization of structure-kinetic relationship--surfing the kinetic map. **2015**, 17, 9-15		32
623	Promiscuity and the conformational rearrangement of drug-like molecules: insight from the protein data bank. **2015**, 10, 238-44		7

622	Discovery of indole-derived pyridopyrazine-1,6-dione secretase modulators that target presenilin. *Bioorganic and Medicinal Chemistry Letters*, **2015**, 25, 908-13	2.9	20
621	Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. *Journal of Medicinal Chemistry*, **2015**, 58, 613-24	8.3	48
620	Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders. *Journal of Medicinal Chemistry*, **2015**, 58, 96-110	8.3	59
619	CNS drug design: balancing physicochemical properties for optimal brain exposure. *Journal of Medicinal Chemistry*, **2015**, 58, 2584-608	8.3	318
618	Tactics in Contemporary Drug Design. **2015**,		11
617	Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. *ACS Medicinal Chemistry Letters*, **2015**, 6, 25-30	4.3	19
616	Structure-Based Design of Type II Inhibitors Applied to Maternal Embryonic Leucine Zipper Kinase. *ACS Medicinal Chemistry Letters*, **2015**, 6, 31-6	4.3	20
615	Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models. *Journal of Medicinal Chemistry*, **2015**, 58, 401-18	8.3	53
614	Discovery of (2S)-8-[(3R)-3-methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrimido[1,2-a]pyrimidin a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. *Journal of Medicinal Chemistry*, **2015**, 58, 376-400	8.3	65
613	Going Small: Using Biophysical Screening to Implement Fragment Based Drug Discovery. **2016**,		1
612	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for Mycobacterium tuberculosis. **2016**, 797-822		3
611	Perspective in Medicinal Chemistry: Structure-Based Drug Design. **2017**, 17, 93-94		2
610	Structure-Based Ligand Design I. **2016**, 15-60		0
609	Process of Fragment-Based Lead Discovery-A Perspective from NMR. *Molecules*, **2016**, 21,	4.8	20
608	Oxazin-5-Ones as a Novel Class of Penicillin Binding Protein Inhibitors: Design, Synthesis and Structure Activity Relationship. **2016**, 11, e0163467		8
607	. **2016**,		18
606	The use of conformationally thermostabilised GPCRs in drug discovery: application to fragment, structure and biophysical techniques. **2016**, 30, 8-13		12
605	Benchmarking the Predictive Power of Ligand Efficiency Indices in QSAR. *Journal of Chemical Information and Modeling*, **2016**, 56, 1576-87	6.1	28

604	Fragment-Based Lead Generation. **2016**, 133-158		
603	Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71. **2016**, 29, 520-527		5
602	The Discovery and Synthesis of the CGRP Receptor Antagonist MK-3207. **2016**, 63-136		3
601	The Role of Biotin in Bacterial Physiology and Virulence: a Novel Antibiotic Target for Mycobacterium tuberculosis. **2016**, 4,		33
600	Discovery of potent, reversible MetAP2 inhibitors via fragment based drug discovery and structure based drug design-Part 1. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2774-2778	2.9	10
599	Quantitative Assessment of the Impact of Fluorine Substitution on P-Glycoprotein (P-gp) Mediated Efflux, Permeability, Lipophilicity, and Metabolic Stability. *Journal of Medicinal Chemistry*, **2016**, 59, 5284-96	8.3	39
598	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains. *Journal of Medicinal Chemistry*, **2016**, 59, 5391-402	8.3	76
597	Structures of endothiapepsin-fragment complexes from crystallographic fragment screening using a novel, diverse and affordable 96-compound fragment library. **2016**, 72, 346-55		22
596	Fragment-Based Screening for Enzyme Inhibitors Using Calorimetry. **2016**, 567, 47-69		6
595	Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach. *Journal of Medicinal Chemistry*, **2016**, 59, 3671-88	8.3	22
594	Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus. *Journal of Medicinal Chemistry*, **2016**, 59, 3689-704	8.3	26
593	Design, discovery, modelling, synthesis, and biological evaluation of novel and small, low toxicity s-triazine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors. **2016**, 24, 2519-29		22
592	Identification and optimisation of a series of N-(4-anilino-2-pyridyl)acetamide activin receptor-like kinase 1 (ALK1) inhibitors. **2016**, 7, 1204-1208		3
591	The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase. *Journal of Medicinal Chemistry*, **2016**, 59, 4867-80	8.3	67
590	Exploitation of a Novel Binding Pocket in Human Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Discovered through X-ray Fragment Screening. *Journal of Medicinal Chemistry*, **2016**, 59, 5356-67	8.3	17
589	An improved model for fragment-based lead generation at AstraZeneca. *Drug Discovery Today*, **2016**, 21, 1272-83	8.8	48
588	Screening and Design of Inhibitor Scaffolds for the Antibiotic Resistance Oxacillinase-48 (OXA-48) through Surface Plasmon Resonance Screening. *Journal of Medicinal Chemistry*, **2016**, 59, 5542-54	8.3	15
587	Badapple: promiscuity patterns from noisy evidence. **2016**, 8, 29		66

586	Compound Prioritization in Single-Concentration Screening Data Using Ligand Efficiency Indexes. *Journal of Chemical Information and Modeling*, **2016**, 56, 1705-13	6.1	2
585	Automatically updating predictive modeling workflows support decision-making in drug design. **2016**, 8, 1779-96		8
584	Derivatives of 3-Amino-2-methylpyridine as BAZ2B Bromodomain Ligands: In Silico Discovery and in Crystallo Validation. *Journal of Medicinal Chemistry*, **2016**, 59, 9919-9927	8.3	18
583	No Denying It: Medicinal Chemistry Training Is in Big Trouble. *Journal of Medicinal Chemistry*, **2016**, 59, 10859-10864	8.3	21
582	The Evolving Role of the Medicinal Chemist. *Progress in Medicinal Chemistry*, **2016**, 55, 193-226	7.3	0
581	NMR in drug discovery: A practical guide to identification and validation of ligands interacting with biological macromolecules. **2016**, 97, 82-125		99
580	Novel approach of fragment-based lead discovery applied to renin inhibitors. **2016**, 24, 6066-6074		3
579	A New Class of Allosteric HIV-1 Integrase Inhibitors Identified by Crystallographic Fragment Screening of the Catalytic Core Domain. **2016**, 291, 23569-23577		15
578	New Methodology for Known Metabolite Identification in Metabonomics/Metabolomics: Topological Metabolite Identification Carbon Efficiency (tMICE). **2016**, 15, 3405-19		11
577	Melting Point Distribution Analysis of Globally Approved and Discontinued Drugs: A Research for Improving the Chance of Success of Drug Design and Discovery. **2016**, 5, 357-68		13
576	Ligand Efficiency Metrics and their Use in Fragment Optimizations. **2016**, 75-98		1
575	BACE Inhibitors. **2016**, 327-354		2
574	Fragment-Based Discovery of Inhibitors of Lactate Dehydrogenase A. **2016**, 391-424		
573	An Integrated Approach for Fragment-Based Lead Discovery: Virtual, NMR, and High-Throughput Screening Combined with Structure-Guided Design. Application to the Aspartyl Protease Renin.. **2016**, 447-486		2
572	Development of Blood-Brain Barrier Permeable Nitrocatechol-Based Catechol O-Methyltransferase Inhibitors with Reduced Potential for Hepatotoxicity. *Journal of Medicinal Chemistry*, **2016**, 59, 7584-97	8.3	21
571	Discovery of novel inhibitors of Aurora kinases with indazole scaffold: In silico fragment-based and knowledge-based drug design. **2016**, 124, 186-199		14
570	Identification of Ligand Binding Hot Spots of the Histamine H Receptor following Structure-Based Fragment Optimization. *Journal of Medicinal Chemistry*, **2016**, 59, 9047-9061	8.3	24
569	Charting the chemical space around the (iso)indoline scaffold, a comprehensive approach towards multitarget directed ligands. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 4211-5	2.9	3

568	The ways and means of fragment-based drug design. **2016**, 167, 28-37		45
567	The Role of Fragment-based Discovery in Lead Finding. **2016**, 1-36		3
566	Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13. **2016**, 11, 1892-8		9
565	Twenty years on: the impact of fragments on drug discovery. **2016**, 15, 605-619		505
564	Fragment Screening in Complex Systems. **2016**, 267-292		1
563	Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules. *Journal of Medicinal Chemistry*, **2016**, 59, 9814-9824	8.3	24
562	Fragment-Based Approach to the Development of an Orally Bioavailable Lactam Inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA). *Journal of Medicinal Chemistry*, **2016**, 59, 10738-10749	8.3	12
561	Potent and Selective Non-hydroxamate Histone Deacetylase 8 Inhibitors. **2016**, 11, 2598-2606		25
560	Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data. **2016**, 66, 195-208		16
559	Debunking the Idea that Ligand Efficiency Indices Are Superior to pIC50 as QSAR Activities. *Journal of Chemical Information and Modeling*, **2016**, 56, 2253-2262	6.1	9
558	Ensemble docking-based virtual screening yields novel spirocyclic JAK1 inhibitors. **2016**, 70, 275-283		4
557	Putative histidine kinase inhibitors with antibacterial effect against multi-drug resistant clinical isolates identified by in vitro and in silico screens. **2016**, 6, 26085		25
556	A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoforms. **2016**, 6, 34701		16
555	NMR Fragment Screening Hit Induces Plasticity of BRD7/9 Bromodomains. **2016**, 17, 1456-63		15
554	Discovery of the first small-molecule CsrA-RNA interaction inhibitors using biophysical screening technologies. **2016**, 8, 931-47		24
553	Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers. *Journal of Medicinal Chemistry*, **2016**, 59, 6501-11	8.3	20
552	GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain. *ACS Medicinal Chemistry Letters*, **2016**, 7, 552-7	4.3	38
551	Lead Properties. **2016**, 283-289		4

550	Fragment-Based Identification of Influenza Endonuclease Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 6444-54	8.3	37
549	A Fluorescence Polarization Assay for Binding to Macrophage Migration Inhibitory Factor and Crystal Structures for Complexes of Two Potent Inhibitors. **2016**, 138, 8630-8		25
548	Introduction: Learnings from the Past Characteristics of Successful Leads. **2016**, 1-12		
547	Small-molecule inhibitors prevent the genotoxic and protumoural effects induced by colibactin-producing bacteria. **2016**, 65, 278-85		48
546	Fragment-Based Design of Selective Nanomolar Ligands of the CREBBP Bromodomain. *Journal of Medicinal Chemistry*, **2016**, 59, 1350-6	8.3	47
545	Compound high-quality criteria: a new vision to guide the development of drugs, current situation. *Drug Discovery Today*, **2016**, 21, 573-84	8.8	27
544	Identification of allosteric ERK2 inhibitors through in silico biased screening and competitive binding assay. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 955-958	2.9	16
543	Novel Phenyl-Substituted 5,6-Dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 Antagonists with Robust Target Engagement in Rat Brain. **2016**, 7, 490-7		19
542	Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 126-32	2.9	16
541	Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 1545-55	8.3	66
540	The Ascaris suum nicotinic receptor, ACR-16, as a drug target: Four novel negative allosteric modulators from virtual screening. *International Journal for Parasitology: Drugs and Drug Resistance*, **2016**, 6, 60-73	4	10
539	Optimization of Inhibitors of Mycobacterium tuberculosis Pantothenate Synthetase Based on Group Efficiency Analysis. **2016**, 11, 38-42		19
538	Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment. **2016**, 87, 39-56		6
537	Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors. *Journal of Medicinal Chemistry*, **2016**, 59, 3272-302	8.3	41
536	An Overview of Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy. *Journal of Medicinal Chemistry*, **2016**, 59, 6595-628	8.3	398
535	Molecular inflation, attrition and the rule of five. **2016**, 101, 22-33		116
534	Prioritization of anti-malarial hits from nature: chemo-informatic profiling of natural products with in vitro antiplasmodial activities and currently registered anti-malarial drugs. **2016**, 15, 50		17
533	Aminoglycoside binding and catalysis specificity of aminoglycoside 2?-phosphotransferase IVa: A thermodynamic, structural and kinetic study. **2016**, 1860, 802-13		8

532	Improving Drug Design: An Update on Recent Applications of Efficiency Metrics, Strategies for Replacing Problematic Elements, and Compounds in Nontraditional Drug Space. **2016**, 29, 564-616		112
531	Development of a potent and selective FLT3 kinase inhibitor by systematic expansion of a non-selective fragment-screening hit. *Bioorganic and Medicinal Chemistry Letters*, **2016**, 26, 2370-4	2.9	6
530	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. **2016**, 121, 823-840		8
529	Integrating Everything: The Molecule Selection Toolkit, a System for Compound Prioritization in Drug Discovery. *Journal of Medicinal Chemistry*, **2016**, 59, 6999-7010	8.3	19
528	Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment Screening. *Journal of Medicinal Chemistry*, **2016**, 59, 2452-67	8.3	14
527	Discovery of a Potent Free Fatty Acid 1 Receptor Agonist with Low Lipophilicity, Low Polar Surface Area, and Robust in Vivo Efficacy. *Journal of Medicinal Chemistry*, **2016**, 59, 2841-6	8.3	17
526	Design and evaluation of novel glutaminase inhibitors. **2016**, 24, 1819-39		39
525	O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1. **2016**, 108, 564-576		27
524	A poised fragment library enables rapid synthetic expansion yielding the first reported inhibitors of PHIP(2), an atypical bromodomain. **2016**, 7, 2322-2330		71
523	Discovery of Subtype Selective Janus Kinase (JAK) Inhibitors by Structure-Based Virtual Screening. *Journal of Chemical Information and Modeling*, **2016**, 56, 234-47	6.1	17
522	STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. **2016**, 44, D380-4		641
521	SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR Inhibitor. *ACS Medicinal Chemistry Letters*, **2016**, 7, 23-7	4.3	48
520	A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry. **2016**, 21, 145-55		28
519	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. *Journal of Medicinal Chemistry*, **2016**, 59, 2849-78	8.3	199
518	Assessing molecular scaffolds for CNS drug discovery. *Drug Discovery Today*, **2017**, 22, 965-969	8.8	25
517	Design and optimization of aspartate N-acetyltransferase inhibitors for the potential treatment of Canavan disease. **2017**, 25, 870-885		10
516	Efficient Approximation of Ligand Rotational and Translational Entropy Changes upon Binding for Use in MM-PBSA Calculations. *Journal of Chemical Information and Modeling*, **2017**, 57, 170-189	6.1	31
515	Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor. **2017**, 139, 3528-3536		46

514	Combination of amino acid/dipeptide with ligustrazine-betulinic acid as antitumor agents. **2017**, 130, 26-38		23
513	Identification of potential inhibitors against the Zika virus using consensus scoring. **2017**, 73, 54-61		22
512	Identifying Loop-Mediated Protein-Protein Interactions Using LoopFinder. **2017**, 1561, 255-277		3
511	Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. *Journal of Medicinal Chemistry*, **2017**, 60, 2983-2992	8.3	81
510	Design, synthesis and biological evaluation of non-covalent AmpC β-lactamases inhibitors. **2017**, 26, 975-986		9
509	Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 1709-1713	2.9	12
508	Antiparasitic Lead Discovery: Toward Optimization of a Chemotype with Activity Against Multiple Protozoan Parasites. *ACS Medicinal Chemistry Letters*, **2017**, 8, 350-354	4.3	16
507	Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure. *ACS Medicinal Chemistry Letters*, **2017**, 8, 316-320	4.3	21
506	Discovery of an Inhibitor of the Proteasome Subunit Rpn11. *Journal of Medicinal Chemistry*, **2017**, 60, 1343-1361	8.3	50
505	The impact of in silico screening in the discovery of novel and safer drug candidates. **2017**, 175, 47-66		58
504	Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. *Journal of Medicinal Chemistry*, **2017**, 60, 4369-4385	8.3	21
503	Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2721-2726	2.9	15
502	Structure-based design and synthesis of acyclic and substituted heterocyclic phosphonates linearly linked to thiazolobenzimidazoles as potent hydrophilic antineoplastic agents. **2017**, 71, 1961-1973		5
501	From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 2974-2981	2.9	30
500	Discovery of indolin-2-one derivatives as potent PAK4 inhibitors: Structure-activity relationship analysis, biological evaluation and molecular docking study. **2017**, 25, 3500-3511		17
499	Discovery of a Potent Nonpeptidomimetic, Small-Molecule Antagonist of Cellular Inhibitor of Apoptosis Protein 1 (cIAP1) and X-Linked Inhibitor of Apoptosis Protein (XIAP). *Journal of Medicinal Chemistry*, **2017**, 60, 4611-4625	8.3	43
498	Discovery of Novel and Selective Adenosine A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening. *Journal of Chemical Information and Modeling*, **2017**, 57, 1474-1487	6.1	35
497	Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach. *Journal of Medicinal Chemistry*, **2017**, 60, 4358-4368	8.3	27

496	Discovery of Highly Potent and Selective Small-Molecule Reversible Factor D Inhibitors Demonstrating Alternative Complement Pathway Inhibition in Vivo. *Journal of Medicinal Chemistry*, **2017**, 60, 5717-5735	8.3	18
495	Discovery and structure-guided fragment-linking of 4-(2,3-dichlorobenzoyl)-1-methyl-pyrrole-2-carboxamide as a pyruvate kinase M2 activator. **2017**, 25, 3540-3546		15
494	Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations. **2017**, 25, 3947-3963		2
493	1,2,4-Triazolo-[1,5-a]pyridine HIF Prolylhydroxylase Domain-1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction. *Journal of Medicinal Chemistry*, **2017**, 60, 5663-5672	8.3	17
492	Thiazole-Based Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Molecular Interactions. **2017**, 12, 1070-1080		5
491	Repurposing Suzuki Coupling Reagents as a Directed Fragment Library Targeting Serine Hydrolases and Related Enzymes. *Journal of Medicinal Chemistry*, **2017**, 60, 5209-5215	8.3	8
490	Application of Structure-Based Design and Parallel Chemistry to Identify a Potent, Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor. *Journal of Medicinal Chemistry*, **2017**, 60, 5673-5698	8.3	22
489	Profiling Drug Binding by Thermodynamics: Key to Understanding. **2017**, 1-36		1
488	Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor. *Journal of Medicinal Chemistry*, **2017**, 60, 3070-3081	8.3	35
487	Predicting "Hot" and "Warm" Spots for Fragment Binding. *Journal of Medicinal Chemistry*, **2017**, 60, 4036-4046	8.3	23
486	CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. *Journal of Medicinal Chemistry*, **2017**, 60, 5943-5954	8.3	59
485	Insight into the remarkable affinity and selectivity of the aminobenzosuberone scaffold for the M1 aminopeptidases family based on structure analysis. **2017**, 85, 1413-1421		7
484	Prospective Evaluation of Free Energy Calculations for the Prioritization of Cathepsin L Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 2485-2497	8.3	82
483	Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 1955-1961	2.9	11
482	Estimation of the protein-ligand interaction energy for model building and validation. **2017**, 73, 195-202		8
481	Discovery of a PCAF Bromodomain Chemical Probe. **2017**, 129, 845-849		9
480	Discovery of a PCAF Bromodomain Chemical Probe. **2017**, 56, 827-831		58
479	The modification of natural products for medical use. **2017**, 7, 119-136		149

478	In Silico Identification of a Novel Hinge-Binding Scaffold for Kinase Inhibitor Discovery. *Journal of Medicinal Chemistry*, **2017**, 60, 8552-8564	8.3	20
477	Design and Synthesis of Ligand Efficient Dual Inhibitors of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Based on Ruxolitinib and Vorinostat. *Journal of Medicinal Chemistry*, **2017**, 60, 8336-8357	8.3	61
476	Small-Molecule Inhibitors of the CD40-CD40L Costimulatory Protein-Protein Interaction. *Journal of Medicinal Chemistry*, **2017**, 60, 8906-8922	8.3	16
475	Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). *Journal of Medicinal Chemistry*, **2017**, 60, 8945-8962	8.3	25
474	Structure optimization of tetrahydropyridoindole-based aldose reductase inhibitors improved their efficacy and selectivity. **2017**, 25, 6353-6360		11
473	Hit-to-Lead Optimization and Discovery of 5-((5-([1,1'-Biphenyl]-4-yl)-6-chloro-1H-benzo[d]imidazol-2-yl)oxy)-2-methylbenzoic Acid (MK-3903): A Novel Class of Benzimidazole-Based Activators of AMP-Activated Protein Kinase. *Journal of Medicinal Chemistry*, **2017**, 60, 8040-8052	8.3	13
472	Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi. *Journal of Medicinal Chemistry*, **2017**, 60, 7284-7299	8.3	22
471	Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective. **2017**, 12, 1087-1104		50
470	Molecular insights into A□protofibril destabilization with a fluorinated compound D744: A molecular dynamics simulation study. **2017**, 30, e2656		18
469	Fragment-Based Discovery and Optimization of Enzyme Inhibitors by Docking of Commercial Chemical Space. *Journal of Medicinal Chemistry*, **2017**, 60, 8160-8169	8.3	25
468	GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP). *Journal of Medicinal Chemistry*, **2017**, 60, 9162-9183	8.3	48
467	Exploring the Relationship between Nicotinic Acetylcholine Receptor Ligand Size, Efficiency, Efficacy, and C-Loop Opening. *Journal of Chemical Information and Modeling*, **2017**, 57, 1947-1956	6.1	8
466	Computational modeling of the bat HKU4 coronavirus 3CL inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus. **2017**, 30, e2644		20
465	A Computational Investigation of Small-Molecule Engagement of Hot Spots at Protein-Protein Interaction Interfaces. *Journal of Chemical Information and Modeling*, **2017**, 57, 2250-2272	6.1	11
464	Identification of pyrazolopyrimidine arylsulfonamides as CC-chemokine receptor 4 (CCR4) antagonists. **2017**, 25, 5327-5340		3
463	Nitro-substituted tetrahydroindolizines and homologs: Design, kinetics, and mechanism of □-glucosidase inhibition. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 3980-3986	2.9	19
462	Dipicolinic Acid Derivatives as Inhibitors of New Delhi Metallo-□-lactamase-1. *Journal of Medicinal Chemistry*, **2017**, 60, 7267-7283	8.3	94
461	Biophysical Screening of a Focused Library for the Discovery of CYP121 Inhibitors as Novel Antimycobacterials. **2017**, 12, 1616-1626		3

460	Identification of a New Zinc Binding Chemotype by Fragment Screening. *Journal of Medicinal Chemistry*, **2017**, 60, 7333-7349	8.3	5
459	Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2. *Journal of Medicinal Chemistry*, **2017**, 60, 10231-10244	8.3	19
458	High-Confidence Protein-Ligand Complex Modeling by NMR-Guided Docking Enables Early Hit Optimization. **2017**, 139, 17824-17833		16
457	Group Additivity in Ligand Binding Affinity: An Alternative Approach to Ligand Efficiency. *Journal of Chemical Information and Modeling*, **2017**, 57, 3086-3093	6.1	18
456	The Discovery of 3-((4-Chloro-3-methoxyphenyl)amino)-1-((3R,4S)-4-cyanotetrahydro-2H-pyran-3-yl)-1H-pyrazole-4-carboxamide, a Highly Ligand Efficient and Efficacious Janus Kinase 1 Selective Inhibitor with Favorable Pharmacokinetic Properties. *Journal of Medicinal Chemistry*, **2017**, 60, 9676-9690	8.3	11
455	Design and Synthesis of Brain Penetrant Trypanocidal N-Myristoyltransferase Inhibitors. *Journal of Medicinal Chemistry*, **2017**, 60, 9790-9806	8.3	9
454	Structural Insight into Inhibition of CsrA-RNA Interaction Revealed by Docking, Molecular Dynamics and Free Energy Calculations. **2017**, 7, 14934		8
453	Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 3629-3635	2.9	4
452	Discovery of phenylsulfonyl acetic acid derivatives with improved efficacy and safety as potent free fatty acid receptor 1 agonists for the treatment of type 2 diabetes. **2017**, 138, 458-479		25
451	Industrial medicinal chemistry insights: neuroscience hit generation at Janssen. *Drug Discovery Today*, **2017**, 22, 1478-1488	8.8	4
450	Fragment-to-Lead Medicinal Chemistry Publications in 2015. *Journal of Medicinal Chemistry*, **2017**, 60, 89-99	8.3	36
449	Synthesis, screening and docking analysis of hispolon analogs as potential antitubercular agents. *Bioorganic and Medicinal Chemistry Letters*, **2017**, 27, 11-15	2.9	11
448	Discovery of nanomolar ligands with novel scaffolds for the histamine H4 receptor by virtual screening. **2017**, 125, 565-572		10
447	Optical Biosensors and Applications to Drug Discovery for Cancer Cases. **2017**, 327-348		4
446	Fragment-Based Lead Discovery. **2017**, 371-439		9
445	Kinetics, Thermodynamics, and Ligand Efficiency Metrics in Drug Discovery. **2017**, 180-211		1
444	Targeting □Secretase (BACE) for the Treatment of Alzheimer□ Disease. **2017**, 326-383		11
443	Diarylethenes Display In Vitro Anti-TB Activity and Are Efficient Hits Targeting the Mycobacterium tuberculosis HU Protein. *Molecules*, **2017**, 22,	4.8	5

442	Synthesis, Molecular Properties Estimations, and Dual Dopamine D and D Receptor Activities of Benzothiazole-Based Ligands. **2017**, 5, 64		7
441	Hit and Lead Generation Strategies. **2017**, 33-63		1
440	Current perspectives in fragment-based lead discovery (FBLD). **2017**, 61, 453-464		89
439	Fragment-Based Drug Design: Strategic Advances and Lessons Learned. **2017**, 212-232		5
438	Multiobjective Optimization of Biological and Physical Properties in Drug Discovery. **2017**, 64-93		
437	Molecular Docking: A Solved Problem?. **2017**, 297-318		1
436	Predicting Target and Chemical Druggability. **2017**, 429-439		2
435	Discovery of , the First Direct Fast Skeletal Muscle Troponin Activator. *ACS Medicinal Chemistry Letters*, **2018**, 9, 354-358	4.3	15
434	Structure Guided Lead Generation toward Nonchiral M. tuberculosis Thymidylate Kinase Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 2753-2775	8.3	20
433	Creation of a Novel Class of Potent and Selective MutT Homologue 1 (MTH1) Inhibitors Using Fragment-Based Screening and Structure-Based Drug Design. *Journal of Medicinal Chemistry*, **2018**, 61, 2533-2551	8.3	17
432	Molecular-Simulation-Driven Fragment Screening for the Discovery of New CXCL12 Inhibitors. *Journal of Chemical Information and Modeling*, **2018**, 58, 683-691	6.1	14
431	4-Amino-7,8-dihydro-1,6-naphthyridin-5(6 H)-ones as Inhaled Phosphodiesterase Type 4 (PDE4) Inhibitors: Structural Biology and Structure-Activity Relationships. *Journal of Medicinal Chemistry*, **2018**, 61, 2472-2489	8.3	10
430	Anti-leishmanial click modifiable thiosemicarbazones: Design, synthesis, biological evaluation and in silico studies. **2018**, 151, 585-600		21
429	A Fragment Library Screening Approach to Identify Selective Inhibitors against an Essential Fungal Enzyme. **2018**, 23, 520-531		5
428	Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. *Journal of Medicinal Chemistry*, **2018**, 61, 6421-6467	8.3	48
427	Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry. *ACS Infectious Diseases*, **2018**, 4, 431-444	5.5	37
426	Computational method for estimating progression saturation of analog series.. **2018**, 8, 5484-5492		10
425	Chemical Space Expansion of Bromodomain Ligands Guided by in Silico Virtual Couplings (AutoCouple). **2018**, 4, 180-188		19

424	Discovery and validation of 2-styryl substituted benzoxazin-4-ones as a novel scaffold for rhomboid protease inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 1417-1422	2.9	12
423	Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold. **2018**, 77, 429-435		13
422	Binding-Site Compatible Fragment Growing Applied to the Design of Adrenergic Receptor Ligands. *Journal of Medicinal Chemistry*, **2018**, 61, 1118-1129	8.3	28
421	Identification of highly potent and orally available free fatty acid receptor 1 agonists bearing isoxazole scaffold. **2018**, 26, 703-711		6
420	When fragments link: a bibliometric perspective on the development of fragment-based drug discovery. *Drug Discovery Today*, **2018**, 23, 1596-1609	8.8	24
419	Discovery of benzimidazole-based Leishmania mexicana cysteine protease CPB2.8CTE inhibitors as potential therapeutics for leishmaniasis. **2018**, 92, 1585-1596		15
418	Lipophilic Efficiency as an Important Metric in Drug Design. *Journal of Medicinal Chemistry*, **2018**, 61, 6401-6420	8.3	111
417	New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2). **2018**, 118, 67-79		11
416	Molecular Insights into hERG Potassium Channel Blockade by Lubeluzole. **2018**, 45, 2233-2245		10
415	Insights into the structural/conformational requirements of cytotoxic oxadiazoles as potential chemotherapeutic target binding agents. **2018**, 1164, 9-22		7
414	Exploration of Novel Human Tyrosinase Inhibitors by Molecular Modeling, Docking and Simulation Studies. **2018**, 10, 68-80		49
413	Fragment-based virtual screening approach and molecular dynamics simulation studies for identification of BACE1 inhibitor leads. *Journal of Biomolecular Structure and Dynamics*, **2018**, 36, 1878-1892	3.6	18
412	Fragment-to-Lead Medicinal Chemistry Publications in 2016. *Journal of Medicinal Chemistry*, **2018**, 61, 1774-1784	8.3	27
411	Molecular modeling studies of pseudouridine isoxazolidinyl nucleoside analogues as potential inhibitors of the pseudouridine 5'-monophosphate glycosidase. **2018**, 91, 519-525		10
410	Structure based virtual screening of the Ebola virus trimeric glycoprotein using consensus scoring. **2018**, 72, 170-180		29
409	Structure-Based Design of 6-Chloro-4-aminoquinazoline-2-carboxamide Derivatives as Potent and Selective p21-Activated Kinase 4 (PAK4) Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 265-285	8.3	28
408	Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonist. **2018**, 26, 798-814		8
407	Causes and Significance of Increased Compound Potency in Cellular or Physiological Contexts. *Journal of Medicinal Chemistry*, **2018**, 61, 1767-1773	8.3	19

406	Fragment-Based Drug Discovery of Phosphodiesterase Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 1415-1424	8.3	14
405	Biophysical screening in fragment-based drug design: a brief overview. **2018**, 11,		9
404	GCDB: a glaucomatous chemogenomics database for in silico drug discovery. **2018**, 2018,		1
403	An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors. *Molecules*, **2018**, 23,	4.8	1
402	In silico identification and experimental validation of hits active against KPC-2 β-lactamase. **2018**, 13, e0203241		5
401	Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach. *Journal of Medicinal Chemistry*, **2018**, 61, 11061-11073	8.3	9
400	Case report on recovery from Japanese encephalitis virus infection by complementary use of phytolacca-mother tincture and in silico analysis. **2018**, 14, 22-28		0
399	Hit-to-Lead: Hit Validation and Assessment. **2018**, 610, 265-309		8
398	3,5-Disubstituted-indole-7-carboxamides as IKKβ Inhibitors: Optimization of Oral Activity via the C3 Substituent. *ACS Medicinal Chemistry Letters*, **2018**, 9, 1164-1169	4.3	4
397	Experimentally Validated Pharmacoinformatics Approach to Predict hERG Inhibition Potential of New Chemical Entities. **2018**, 9, 1035		18
396	Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 3458-3462	2.9	11
395	A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors. *Journal of Medicinal Chemistry*, **2018**, 61, 8374-8389	8.3	29
394	Fragment-Based Discovery of a Regulatory Site in Thioredoxin Glutathione Reductase Acting as "Doorstop" for NADPH Entry. *ACS Chemical Biology*, **2018**, 13, 2190-2202	4.9	14
393	Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition. **2018**, 26, 3021-3029		6
392	Cheminformatic Insight into the Differences between Terrestrial and Marine Originated Natural Products. *Journal of Chemical Information and Modeling*, **2018**, 58, 1182-1193	6.1	32
391	'Tethering' fragment-based drug discovery to identify inhibitors of the essential respiratory membrane protein type II NADH dehydrogenase. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 2239-2243	2.9	8
390	Hot Spot-Based Design of Small-Molecule Inhibitors for Protein-Protein Interactions. **2018**, 53-71		0
389	Applications of NMR Spectroscopy in FBDD. **2018**, 2211-2231		2

388	Targeting Protein-Protein Interactions by Small Molecules. **2018**,		5
387	Design of Novel Dual-Target Hits Against Malaria and Tuberculosis Using Computational Docking. **2018**, 419-442		
386	Design, synthesis, and biological evaluation of novel oxadiazole- and thiazole-based histamine HR ligands. **2018**, 26, 4034-4046		14
385	LeadOp+R: Structure-Based Lead Optimization With Synthetic Accessibility. **2018**, 9, 96		2
384	Lead-like Drugs: A Perspective. *Journal of Medicinal Chemistry*, **2018**, 61, 10375-10384	8.3	29
383	NMR-Fragment Based Virtual Screening: A Brief Overview. *Molecules*, **2018**, 23,	4.8	28
382	VSpipe, an Integrated Resource for Virtual Screening and Hit Selection: Applications to Protein Tyrosine Phospahatase Inhibition. *Molecules*, **2018**, 23,	4.8	8
381	New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8. **2018**, 156, 587-597		7
380	Structure-Activity Relationships and Docking Studies of Hydroxychavicol and Its Analogs as Xanthine Oxidase Inhibitors. **2018**, 66, 741-747		8
379	Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery. *Molecules*, **2018**, 23,	4.8	50
378	PET Imaging of T Cells: Target Identification and Feasibility Assessment. **2018**, 13, 1566-1579		1
377	Investigation of synergistic antimicrobial effects of the drug combinations of meropenem and 1,2-benzisoselenazol-3(2H)-one derivatives on carbapenem-resistant Enterobacteriaceae producing NDM-1. **2018**, 155, 285-302		25
376	Identification of allosteric inhibitors of the ecto-5'-nucleotidase (CD73) targeting the dimer interface. **2018**, 14, e1005943		15
375	Molecular dynamics and combined docking studies for the identification of Zaire ebola virus inhibitors. *Journal of Biomolecular Structure and Dynamics*, **2019**, 37, 3029-3040	3.6	15
374	Overview of the Development of Glutaminase Inhibitors: Achievements and Future Directions. *Journal of Medicinal Chemistry*, **2019**, 62, 1096-1115	8.3	50
373	How Size Matters: Diversity for Fragment Library Design. *Molecules*, **2019**, 24,	4.8	9
372	Design of selective PI3K□inhibitors using an iterative scaffold-hopping workflow. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 2575-2580	2.9	10
371	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models. *Journal of Medicinal Chemistry*, **2019**, 62, 8557-8577	8.3	37

370	FtsZ inhibitors as a new genera of antibacterial agents. **2019**, 91, 103169		32
369	Using Physicochemical Measurements to Influence Better Compound Design. **2019**, 24, 791-801		11
368	A Receptor Model With Binding Affinity, Activation Efficacy, and Signal Amplification Parameters for Complex Fractional Response Versus Occupancy Data. **2019**, 10, 605		14
367	Computational Screening of Potential Inhibitors of β-N-Acetyl-D-Hesosaminidases Using Combined Core-Fragment Growth and Pharmacophore Restraints. **2019**, 189, 1262-1273		0
366	Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. **2019**, 179, 608-622		10
365	Pharmacoinformatics-based identification of anti-bacterial catalase-peroxidase enzyme inhibitors. **2019**, 83, 107136		8
364	Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors. **2019**, 184, 111756		12
363	Shortcuts to schistosomiasis drug discovery: The state-of-the-art. **2019**, 139-180		2
362	Discovery and Pharmacophore Mapping of a Low-Nanomolar Inhibitor of P. falciparum Growth. **2019**, 14, 1982-1994		4
361	Discovery of Small Molecule Antagonists of the USP5 Zinc Finger Ubiquitin-Binding Domain. *Journal of Medicinal Chemistry*, **2019**, 62, 10144-10155	8.3	2
360	Differentiation of the Agonists and Antagonists of the α7 Nicotinic Acetylcholine Receptor. **2019**, 18, 1193-1198		
359	Pushing the Ligand Efficiency Metrics: Relative Group Contribution (RGC) Model as a Helpful Strategy to Promote a Fragment "Rescue" Effect. **2019**, 7, 564		3
358	Practical approaches to evaluating and optimizing brain exposure in early drug discovery. **2019**, 182, 111643		10
357	Discovery of Benzamidine- and 1-Aminoisoquinoline-Based Human MAS-Related G-Protein-Coupled Receptor X1 (MRGPRX1) Agonists. *Journal of Medicinal Chemistry*, **2019**, 62, 8631-8641	8.3	4
356	Fraction Lipophilicity Index (FLI). A drug-like metric for orally administered ionizable drugs. **2019**, 30, 643-653		1
355	Discovery of Ligand-Efficient Scaffolds for the Design of Novel Uridine Nucleoside Ribohydrolase Inhibitors Using Fragment Screening. **2019**, 4, 16226-16232		3
354	Pharmacoinformatics-based identification of potential bioactive compounds against Ebola virus protein VP24. **2019**, 113, 103414		20
353	Key Topics in Molecular Docking for Drug Design. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	84

352	Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies. **2019**, 34, 429-437		41
351	Ligand-Efficient Inhibitors of Trichomonas vaginalis Adenosine/Guanosine Preferring Nucleoside Ribohydrolase. *ACS Infectious Diseases*, **2019**, 5, 345-352	5.5	5
350	The nature of ligand efficiency. **2019**, 11, 8		28
349	New Rigid Nicotine Analogues, Carrying a Norbornane Moiety, Are Potent Agonists of α7 and α3β4* Nicotinic Receptors. *Journal of Medicinal Chemistry*, **2019**, 62, 1887-1901	8.3	4
348	Dexibuprofen amide derivatives as potential anticancer agents: synthesis, in silico docking, bioevaluation, and molecular dynamic simulation. **2019**, 13, 1643-1657		8
347	Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold. *ACS Medicinal Chemistry Letters*, **2019**, 10, 893-898	4.3	11
346	Fragment-based drug design of nature-inspired compounds. **2019**, 4,		2
345	Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. **2019**, 7, 26		3
344	Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases. **2019**, 34, 1010-1017		6
343	Fraction Lipophilicity Index (FLI). **2019**, 4, 41-66		
342	Discovery of a Thiadiazole-Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models. *Journal of Medicinal Chemistry*, **2019**, 62, 6540-6560	8.3	13
341	Identification of promising anti-DNA gyrase antibacterial compounds using design, molecular docking and molecular dynamics studies. *Journal of Biomolecular Structure and Dynamics*, **2020**, 38, 1798-1809	3.6	18
340	High-throughput screening of the Plasmodium falciparum cGMP-dependent protein kinase identified a thiazole scaffold which kills erythrocytic and sexual stage parasites. **2019**, 9, 7005		25
339	Cheminformatics techniques in antimalarial drug discovery and development from natural products 1: basic concepts. **2019**, 4,		1
338	Beyond the Flavour: The Potential Druggability of Chemosensory G Protein-Coupled Receptors. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	37
337	High-Performance Modelling and Simulation for Big Data Applications. **2019**,		2
336	In Silico Target Druggability Assessment: From Structural to Systemic Approaches. **2019**, 1953, 63-88		4
335	Properties of FDA-approved small molecule protein kinase inhibitors. *Pharmacological Research*, **2019**, 144, 19-50	10.2	247

334	FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation. *Journal of Medicinal Chemistry*, **2019**, 62, 3741-3752	8.3	32
333	Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design. *Drug Discovery Today*, **2019**, 24, 1081-1086	8.8	37
332	A combinatorial approach for the discovery of drug-like inhibitors of 15-lipoxygenase-1. **2019**, 174, 45-55		8
331	Cloud-Based High Throughput Virtual Screening in Novel Drug Discovery. **2019**, 250-278		8
330	Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines. **2019**, 88, 102918		5
329	Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1497-1501	2.9	12
328	Accelerated drug discovery by rapid candidate drug identification. *Drug Discovery Today*, **2019**, 24, 1237-1241	8.8	14
327	Cu-mediated synthesis of differentially substituted diazepines as AChE inhibitors; validation through molecular docking and Lipinski's filter to develop novel anti-neurodegenerative drugs. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1308-1312	2.9	16
326	Targeting ERK1/2 protein-serine/threonine kinases in human cancers. *Pharmacological Research*, **2019**, 142, 151-168	10.2	100
325	Structure-based design, synthesis and biological evaluation of a novel series of isoquinolone and pyrazolo[4,3-c]pyridine inhibitors of fascin 1 as potential anti-metastatic agents. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 1023-1029	2.9	19
324	Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase. **2019**, 167, 161-186		48
323	The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. **2019**, 27, 1456-1478		12
322	Identification of the 2-Benzoxazol-2-yl-phenol Scaffold as New Hit for JMJD3 Inhibition. *ACS Medicinal Chemistry Letters*, **2019**, 10, 601-605	4.3	12
321	Evaluating the Advantages of Using 3D-Enriched Fragments for Targeting BET Bromodomains. *ACS Medicinal Chemistry Letters*, **2019**, 10, 1648-1654	4.3	18
320	Concepts and Core Principles of Fragment-Based Drug Design. *Molecules*, **2019**, 24,	4.8	45
319	Small-Molecule Intervention At The Dimerization Interface Of Survivin By Novel Rigidized Scaffolds. **2019**, 13, 4247-4263		3
318	Benford's law in medicinal chemistry: Implications for drug design. **2019**, 11, 2247-2253		4
317	Medicines discovery for auditory disorders: Challenges for industry. **2019**, 146, 3652		8

316	Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs. *Journal of Medicinal Chemistry*, **2019**, 62, 1701-1714	8.3	170
315	Novel, potent, selective, and brain penetrant phosphodiesterase 10A inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 406-412	2.9	2
314	Rhodium-Catalyzed Cascade Annulation Reaction via C□H Activation of Azobenzenes with Terminal Alkynes: A Synthesis of Indolo[1,2-b]cinnolines. **2019**, 361, 451-455		7
313	Analysis of solvent-exposed and buried co-crystallized ligands: a case study to support the design of novel protein-protein interaction inhibitors. *Drug Discovery Today*, **2019**, 24, 551-559	8.8	11
312	Fragment-to-Lead Medicinal Chemistry Publications in 2017. *Journal of Medicinal Chemistry*, **2019**, 62, 3857-3872	8.3	27
311	NMR screening and studies of target□ligand interactions. **2019**, 88, 59-98		6
310	Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 1138-1166	8.3	52
309	Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1. **2019**, 161, 479-492		11
308	Fragment-Based Drug Discovery: Advancing Fragments in the Absence of Crystal Structures. **2019**, 26, 9-15		53
307	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. **2019**, 93, 430-437		8
306	Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists. **2019**, 162, 631-649		8
305	Applications of Metabolic Phenotyping in Pharmaceutical Research and Development. **2019**, 407-447		1
304	Discovery of potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitors possessing a key intramolecular hydrogen bond - Part 2. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 674-680	2.9	3
303	Interaction between 1-pyrenesulfonic acid and albumin: Moving inside the protein. **2019**, 208, 243-254		10
302	In silico screening of a novel scaffold for fructose-1,6-bisphosatase (FBPase) inhibitors. **2019**, 86, 142-148		4
301	The Drug Discovery Process. **2019**, 323-371		
300	NAOMInext - Synthetically feasible fragment growing in a structure-based design context. **2019**, 163, 747-762		4
299	Advances in Lead Generation. *Bioorganic and Medicinal Chemistry Letters*, **2019**, 29, 517-524	2.9	18

298	Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu) X-ray Structures. *Journal of Medicinal Chemistry*, **2019**, 62, 207-222	8.3	48
297	Virtual screening in drug-likeness and structure/activity relationship of pyridazine derivatives as Anti-Alzheimer drugs. **2019**, 31, 595-601		17
296	Designing of benzothiazole derivatives as promising EGFR tyrosine kinase inhibitors: a pharmacoinformatics study. *Journal of Biomolecular Structure and Dynamics*, **2020**, 38, 1365-1374	3.6	5
295	Development of ERK1/2 inhibitors as a therapeutic strategy for tumour with MAPK upstream target mutations. **2020**, 28, 154-165		7
294	Flexible Fragment Growing Boosts Potency of Quorum-Sensing Inhibitors against Pseudomonas aeruginosa Virulence. **2020**, 15, 188-194		13
293	Citral Inhibition of Human Salivary Aldehyde Dehydrogenase. **2020**, 78, 31-42		5
292	Development of a Web-Based Laboratory Class to Reduce the Challenges in Teaching Fragment-Based Drug Design. **2020**, 97, 427-436		9
291	Fragment-to-Lead Medicinal Chemistry Publications in 2018. *Journal of Medicinal Chemistry*, **2020**, 63, 4430-4444	8.3	37
290	Computational screening of promising beta-secretase 1 inhibitors through multi-step molecular docking and molecular dynamics simulations - Pharmacoinformatics approach. **2020**, 1205, 127660		11
289	Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. *Pharmacological Research*, **2020**, 152, 104609	10.2	244
288	Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead. *Molecules*, **2019**, 25,	4.8	3
287	Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors. **2020**, 28, 115257		2
286	Fluorescent ligands: Bringing light to emerging GPCR paradigms. **2020**, 177, 978-991		26
285	. **2020**,		0
284	Setup and Validation of a Reliable Docking Protocol for the Development of Neuroprotective Agents by Targeting the Sigma-1 Receptor (S1R). *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
283	Fragment-based lead discovery of a novel class of small molecule antagonists of neuropeptide B/W receptor subtype 1 (GPR7). *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127510	2.9	5
282	Solution structure of the Hop TPR2A domain and investigation of target druggability by NMR, biochemical and in silico approaches. **2020**, 10, 16000		4
281	Alkaloids from as Potential Inhibitors of SARS-CoV-2 Viral Proteins: An Study. **2020**, 2020, 5324560		30

280	Design and Synthesis of a Highly Selective and -Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of Proteins. *Journal of Medicinal Chemistry*, **2020**, 63, 9070-9092	8.3	21
279	Cyanobacterial metabolites as promising drug leads against the M and PL of SARS-CoV-2: an analysis. *Journal of Biomolecular Structure and Dynamics*, **2021**, 39, 6218-6230	3.6	24
278	Pharmacokinetics (ADME). **2020**, 133-224		
277	Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs. **2020**, 13, 11-25		10
276	Fragment-to-Lead Medicinal Chemistry Publications in 2019. *Journal of Medicinal Chemistry*, **2020**, 63, 15494-15507	8.3	18
275	Understanding binding between donepezil and human ferritin: molecular docking and molecular dynamics simulation approach. *Journal of Biomolecular Structure and Dynamics*, **2020**, 1-9	3.6	2
274	Discovery of Novel and Highly Selective Cyclopropane ALK Inhibitors through a Fragment-Assisted, Structure-Based Drug Design. **2020**, 5, 31984-32001		2
273	Highly Potent and Selective -Aryl Oxamic Acid-Based Inhibitors for Protein Tyrosine Phosphatase B. *Journal of Medicinal Chemistry*, **2020**, 63, 9212-9227	8.3	9
272	Chemical Biology Toolsets for Drug Discovery and Target Identification. **2020**,		1
271	The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor. *Journal of Medicinal Chemistry*, **2020**, 63, 9093-9126	8.3	23
270	Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. **2020**, 288, 198102		43
269	Design, Synthesis, and Pharmacological Characterization of a Neutral, Non-Prodrug Thrombin Inhibitor with Good Oral Pharmacokinetics. *Journal of Medicinal Chemistry*, **2020**, 63, 12574-12594	8.3	6
268	InstaDock: A single-click graphical user interface for molecular docking-based virtual high-throughput screening. **2021**, 22,		37
267	Optimization of kinetic stabilizers of tetrameric transthyretin: A prospective ligand efficiency-guided approach. **2020**, 28, 115794		3
266	Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties. *Journal of Medicinal Chemistry*, **2020**, 63, 12957-12977	8.3	14
265	Finding of Key Interaction Mediated α4 and β2 Nicotinic Acetylcholine Receptor Ligand Selectivity of Quinuclidine-Triazole Chemotype. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	1
264	Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery. *Molecules*, **2020**, 25,	4.8	2
263	Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models. *Journal of Medicinal Chemistry*, **2020**, 63, 10246-10262	8.3	16

262	Diameter Is a Key 3D Characteristic for Assessments of Efficient Inhibitors of Protein-Protein Interactions. *Journal of Chemical Information and Modeling*, **2020**, 60, 4785-4790	6.1	
261	Pharmacological inhibition of syntenin PDZ2 domain impairs breast cancer cell activities and exosome loading with syndecan and EpCAM cargo. **2020**, 10, e12039		7
260	LEADS-FRAG: A Benchmark Data Set for Assessment of Fragment Docking Performance. *Journal of Chemical Information and Modeling*, **2020**, 60, 6544-6554	6.1	3
259	Biophysical Elucidation of Fibrillation Inhibition by Sugar Osmolytes in □Lactalbumin: Multispectroscopic and Molecular Docking Approaches. **2020**, 5, 26871-26882		5
258	Comprehensive and High-Throughput Exploration of Chemical Space Using Broadband F NMR-Based Screening. **2020**, 59, 14809-14817		14
257	Discovery of new potential CDK2/VEGFR2 type II inhibitors by fragmentation and virtual screening of natural products. *Journal of Biomolecular Structure and Dynamics*, **2021**, 39, 3285-3299	3.6	5
256	Comprehensive and High-Throughput Exploration of Chemical Space Using Broadband 19F NMR-Based Screening. **2020**, 132, 14919-14927		2
255	Evaluation of new antihypertensive drugs designed using Thermolysin as a target. **2020**, 28, 582-592		6
254	Protein-fragment complex structures derived by NMR molecular replacement. **2020**, 11, 591-596		4
253	Stabilizing Inactive Conformations of MALT1 as an Effective Approach to Inhibit Its Protease Activity. **2020**, 3, 2000078		2
252	15. Cheminformatics techniques in antimalarial drug discovery and development from natural products 1: basic concepts. **2020**, 381-396		
251	Novel molecular signatures and potential therapeutics in renal cell carcinomas: Insights from a comparative analysis of subtypes. **2020**, 112, 3166-3178		3
250	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. *Journal of Medicinal Chemistry*, **2020**, 63, 8088-8113	8.3	7
249	Efficient affinity ranking of fluorinated ligands by F NMR: CSAR and FastCSAR. **2020**, 74, 579-594		5
248	LigBuilder V3: A Multi-Target Drug Design Approach. **2020**, 8, 142		19
247	Pharmacoinformatics and molecular dynamic simulation studies to identify potential small-molecule inhibitors of WNK-SPAK/OSR1 signaling that mimic the RFQV motifs of WNK kinases. **2020**, 13, 5107-5117		9
246	Exploring the binding mode of triflamide derivatives at the active site of Topo I and Topo II enzymes: In silico analysis and precise molecular docking. **2020**, 132, 1		3
245	Identification of potential inhibitors of human methionine aminopeptidase (type II) for cancer therapy: Structure-based virtual screening, ADMET prediction and molecular dynamics studies. **2020**, 86, 107244		5

244	Molecular structure, drug likeness and QSAR modeling of 1,2-diazole derivatives as inhibitors of enoyl-acyl carrier protein reductase. **2020**, 32, 2301-2310		4
243	Cov_FB3D: A De Novo Covalent Drug Design Protocol Integrating the BA-SAMP Strategy and Machine-Learning-Based Synthetic Tractability Evaluation. *Journal of Chemical Information and Modeling*, **2020**, 60, 4388-4402	6.1	7
242	De novo design based identification of potential HIV-1 integrase inhibitors: A pharmacoinformatics study. **2020**, 88, 107319		6
241	Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp character and an exquisite selectivity profile. *Bioorganic and Medicinal Chemistry Letters*, **2020**, 30, 127405	2.9	4
240	Druggability Assessment in TRAPP Using Machine Learning Approaches. *Journal of Chemical Information and Modeling*, **2020**, 60, 1685-1699	6.1	14
239	Structure-guided screening of chemical database to identify NS3-NS2B inhibitors for effective therapeutic application in dengue infection. **2020**, 33, e2838		16
238	Strategies to Support Fragment-to-Lead Optimization in Drug Discovery. **2020**, 8, 93		48
237	Synthesis, biochemical, pharmacological characterization and in silico profile modelling of highly potent opioid orvinol and thevinol derivatives. **2020**, 191, 112145		3
236	Lipophilic Metabolic Efficiency (LipMetE) and Drug Efficiency Indices to Explore the Metabolic Properties of the Substrates of Selected Cytochrome P450 Isoforms. **2020**, 5, 179-188		4
235	Combining Structural, Thermodynamic, and Kinetic Information to Drive Hit-to-Lead Progression. **2020**, 99-124		1
234	Impact of Recently Determined Crystallographic Structures of GPCRs on Drug Discovery. **2020**, 449-477		1
233	Establishing Trypanosoma cruzi farnesyl pyrophosphate synthase as a viable target for biosensor driven fragment-based lead discovery. *Protein Science*, **2020**, 29, 991-1003	6.3	2
232	Lead Identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline Derivatives as DNA Gyrase Inhibitors: Hit-to-Lead Generation Involving Thermodynamic Evaluation. **2020**, 5, 10145-10159		15
231	Applied Biophysical Methods in Fragment-Based Drug Discovery. **2020**, 25, 471-490		6
230	Pharmacophore modeling of JAK1: A target infested with activity-cliffs. **2020**, 99, 107615		5
229	Protein ligand interaction analysis against new CaMKK2 inhibitors by use of X-ray crystallography and the fragment molecular orbital (FMO) method. **2020**, 99, 107599		8
228	Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources. *Journal of Medicinal Chemistry*, **2020**, 63, 10158-10169	8.3	18
227	Identification of naturally originated molecules as □aminobutyric acid receptor antagonist. *Journal of Biomolecular Structure and Dynamics*, **2021**, 39, 911-922	3.6	11

226	Water-soluble inhibitors of ABCG2 (BCRP) - A fragment-based and computational approach. **2021**, 210, 112958		8
225	Approaches to mitigate the risk of serious adverse reactions in covalent drug design. **2021**, 16, 275-287		8
224	Exploration of inhibitory action of Azo imidazole derivatives against COVID-19 main protease (M): A computational study. **2021**, 1224, 129178		11
223	Using NMR Spectroscopy in the Fragment-Based Drug Discovery of Small-Molecule Anticancer Targeted Therapies. **2021**, 16, 725-742		5
222	Novel potent (dihydro)benzofuranyl piperazines as human histamine receptor ligands - Functional characterization and modeling studies on H and H receptors. **2021**, 30, 115924		3
221	Identification of Novel Fragments Binding to the PDZ1-2 Domain of PSD-95. **2021**, 16, 949-954		
220	Identification of selective Lyn inhibitors from the chemical databases through integrated molecular modelling approaches. **2021**, 32, 1-27		0
219	Identification of a novel binding mechanism of Quinoline based molecules with lactate dehydrogenase of. *Journal of Biomolecular Structure and Dynamics*, **2021**, 39, 348-356	3.6	17
218	Query-guided protein-protein interaction inhibitor discovery. **2021**, 12, 4753-4762		1
217	A Systematic Framework for Heart Disease Prediction Using Big Data Analytics. **2021**, 277-305		
216	New ecdysone receptor agonists: a computational approach for rational discovery of insecticides for crop protection.		2
215	Synthesis and biological evaluation of thiazolidinedione derivatives with high ligand efficiency to PhzS. **2021**, 36, 1217-1229		1
214	A probable means to an end: exploring P131 pharmacophoric scaffold to identify potential inhibitors of Cryptosporidium parvum inosine monophosphate dehydrogenase. **2021**, 27, 35		0
213	Application of Docking for Lead Optimization. **2021**, 271-294		0
212	Holistic Assessment of Compound Properties□n Vitro to In Vivo Pharmacology. **2021**,		
211	Theoretical Evaluation of Novel Thermolysin Inhibitors from . Possible Antibacterial Agents. *Molecules*, **2021**, 26,	4.8	1
210	F NMR viewed through two different lenses: ligand-observed and protein-observed F NMR applications for fragment-based drug discovery. **2021**, 2, 1312-1330		5
209	Emergent synthetic methods for the modular advancement of sp-rich fragments. **2021**, 12, 4646-4660		15

208	Structure□ctivity relationships and drug design. **2021**, 129-153		0
207	Design, synthesis and biological evaluation of 1-pyrrolo[2,3-]pyridine derivatives as potent fibroblast growth factor receptor inhibitors.. **2021**, 11, 20651-20661		
206	Multiple Target Drug Design Using LigBuilder 3. **2021**, 2266, 279-298		
205	Physicochemical Profiling and Comparison of Research Antiplasmodials and Advanced Stage Antimalarials with Oral Drugs. **2021**, 6, 6424-6437		0
204	N,N?-dialkyl-2-thiobarbituric acid based sulfonamides as potential SARS-CoV-2 main protease inhibitors. **2021**, 99, 330-345		1
203	Trehalose Restrains the Fibril Load towards □Lactalbumin Aggregation and Halts Fibrillation in a Concentration-Dependent Manner. **2021**, 11,		2
202	Multispectroscopic and Molecular Docking Insight into Elucidating the Interaction of Irisin with Rivastigmine Tartrate: A Combinational Therapy Approach to Fight Alzheimer's Disease. **2021**, 6, 7910-7921		4
201	A computational study on active constituents of and as inhibitors of SARS-CoV-2 main protease. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-12	3.6	1
200	Alkaloids Used as Medicines: Structural Phytochemistry Meets Biodiversity-An Update and Forward Look. *Molecules*, **2021**, 26,	4.8	13
199	Ligand efficiency indices for effective drug discovery: a unifying vector formulation. **2021**, 16, 763-775		0
198	A Molecular Modeling Approach to Identify Potential Antileishmanial Compounds Against the Cell Division Cycle (cdc)-2-Related Kinase 12 (CRK12) Receptor of. **2021**, 11,		8
197	Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition. **2021**, 700, 108771		6
196	Elucidating the Interaction of Human Ferritin with Quercetin and Naringenin: Implication of Natural Products in Neurodegenerative Diseases: Molecular Docking and Dynamics Simulation Insight. **2021** , 6, 7922-7930		20
195	Discovery and resistance mechanism of a selective CDK12 degrader. **2021**, 17, 675-683		16
194	Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. *Pharmacological Research*, **2021**, 165, 105463	10.2	107
193	In vitro study of Hesperetin and Hesperidin as inhibitors of zika and chikungunya virus proteases. **2021**, 16, e0246319		8
192	Computer simulation to identify selective inhibitor for human phosphodiesterase10A. *Journal of Molecular Liquids*, **2021**, 328, 115419	6	10
191	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. *Journal of Medicinal Chemistry*, **2021**, 64, 4333-4358	8.3	6

190	Advances in Multiobjective Optimization for Drug Discovery and Development. 1-25		0
189	NMR-Based Screening and Drug Discovery. 1-83		
188	Fragment-Based Lead Discovery. 1-35		
187	From High-Throughput Screening to Target Validation: Benzo[]isothiazoles as Potent and Selective Agonists of Human Transient Receptor Potential Cation Channel Subfamily M Member 5 Possessing In Vivo Gastrointestinal Prokinetic Activity in Rodents. *Journal of Medicinal Chemistry*, **2021**, 64, 5931-5955	8.3	0
186	NMR Reporter Assays for the Quantification of Weak-Affinity Receptor-Ligand Interactions. **2021**, 26, 1020-1028		0
185	Deconstructing Noncovalent Kelch-like ECH-Associated Protein 1 (Keap1) Inhibitors into Fragments to Reconstruct New Potent Compounds. *Journal of Medicinal Chemistry*, **2021**, 64, 4623-4661	8.3	6
184	Reckoning Glutamyl-S-allylcysteine as a potential main protease (m) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation. **2021**, 47, 699-710		5
183	Inhibitor development of MTH1 via high-throughput screening with fragment based library and MTH1 substrate binding cavity. **2021**, 110, 104813		1
182	Target-Based Evaluation of "Drug-Like" Properties and Ligand Efficiencies. *Journal of Medicinal Chemistry*, **2021**, 64, 7210-7230	8.3	9
181	Apigenin and Structurally Related Flavonoids Allosterically Potentiate the Function of Human -Nicotinic Acetylcholine Receptors Expressed in SH-EP1 Cells. **2021**, 10,		1
180	Schistosomiasis Drug Discovery in the Era of Automation and Artificial Intelligence. **2021**, 12, 642383		2
179	Automated Generation of Novel Fragments Using Screening Data, a Dual SMILES Autoencoder, Transfer Learning and Syntax Correction. *Journal of Chemical Information and Modeling*, **2021**, 61, 2547-2559	6.1	1
178	Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy. *Molecules*, **2021**, 26,	4.8	5
177	Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B. *Journal of Medicinal Chemistry*, **2021**, 64, 8971-8991	8.3	7
176	and Studies of Flavonoids Isolated from as Potential Antidiarrheal Agents. **2021**, 6, 15617-15624		2
175	Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies. *Pharmacological Research*, **2021**, 168, 105579	10.2	13
174	Mechanistic insight into the binding of graphene oxide with human serum albumin: Multispectroscopic and molecular docking approach. **2021**, 256, 119750		10
173	The role of reversible and irreversible covalent chemistry in targeted protein degradation. **2021**, 28, 952-968		11

172	Benzosuberene-sulfone analogues synthesis from Cedrus deodara oil and their therapeutic evaluation by computational analysis to treat type 2 diabetes. **2021**, 112, 104860		2
171	Development of AC265347-Inspired Calcium-Sensing Receptor Ago-Positive Allosteric Modulators. **2021**, 16, 3451-3462		0
170	DrugPred_RNA-A Tool for Structure-Based Druggability Predictions for RNA Binding Sites. *Journal of Chemical Information and Modeling*, **2021**, 61, 4068-4081	6.1	0
169	Inhibitors of Human Divalent Metal Transporters DMT1 (SLC11A2) and ZIP8 (SLC39A8) from a GDB-17 Fragment Library. **2021**, 16, 3306-3314		4
168	A computational approach for rational discovery of inhibitors for non-structural protein 1 of SARS-CoV-2. **2021**, 135, 104555		27
167	An Experimental Toolbox for Structure-Based Hit Discovery for P. aeruginosa FabF, a Promising Target for Antibiotics. **2021**, 16, 2715-2726		2
166	Exploring the molecular interactions of Galantamine with human Transferrin: In-silico and in vitro insight. *Journal of Molecular Liquids*, **2021**, 335, 116227	6	2
165	Febuxostat-based amides and some derived heterocycles targeting xanthine oxidase and COX inhibition. Synthesis, in vitro and in vivo biological evaluation, molecular modeling and in silico ADMET studies. **2021**, 113, 104948		1
164	Discovery of the Bruton's Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 ()-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3-1,2,4-triazol-3-one, by Fragment-Based Drug Design. *Journal of Medicinal Chemistry*, **2021**, 64, 12893-12902	8.3	4
163	SAR study of small molecule inhibitors of the programmed cell death-1/programmed cell death-ligand 1 interaction. **2021**, 98, 914-929		
162	Fragment-to-lead tailored in silico design.. **2021**, 40, 44-57		0
161	Design, synthesis and biological evaluation of novel thiohydantoin derivatives as antiproliferative agents: A combined experimental and theoretical assessments. **2021**, 1249, 131574		5
160	A knowledge-based, structural-aided discovery of a novel class of 2-phenylimidazo[1,2-a]pyridine-6-carboxamide H-PGDS inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2021**, 47, 128113	2.9	
159	Comprehensive Approach of F Nuclear Magnetic Resonance, Enzymatic, and Methods for Site-Specific Hit Selection and Validation of Fragment Molecules that Inhibit Methionine Lyase Activity. *Journal of Medicinal Chemistry*, **2021**, 64, 14299-14310	8.3	
158	Inhibition of Dethiobiotin Synthase (DTBS): Toward Next-Generation Antituberculosis Agents. *ACS Chemical Biology*, **2021**, 16, 2339-2347	4.9	0
157	Fragment-Based Discovery of Small Molecules Bound to T-Cell Immunoglobulin and Mucin Domain-Containing Molecule 3 (TIM-3). *Journal of Medicinal Chemistry*, **2021**, 64, 14757-14772	8.3	1
156	Probing the interaction of memantine, an important Alzheimer's drug, with human serum albumin: In silico and in vitro approach. *Journal of Molecular Liquids*, **2021**, 340, 116888	6	8
155	Recognition of distinct chemical molecules as inhibitors for KIT receptor mutants D816H/Y/V: A simulation approach. *Journal of Molecular Liquids*, **2021**, 339, 116317	6	5

154	Discovery and development of 2-aminobenzimidazoles as potent antimalarials. **2021**, 221, 113518		1
153	Spectroscopic, calorimetric and in silico insight into the molecular interactions of Memantine with human transferrin: Implications of Alzheimer's drugs. **2021**, 190, 660-666		2
152	Structure-aided optimization of non-nucleoside M.tuberculosis thymidylate kinase inhibitors. **2021**, 225, 113784		1
151	Generating a High-Quality Compound Collection. 9-21		3
150	Site Identification by Ligand Competitive Saturation (SILCS) simulations for fragment-based drug design. **2015**, 1289, 75-87		21
149	CHAPTER 1:Different Flavours of Fragments. **2015**, 1-18		1
148	CHAPTER 2:Getting the Most Value from Your Screens: Advances in Hardware, Software, and Methodologies to Enhance Surface Plasmon Resonance Based Fragment Screening and Hit-to-Lead Support. **2015**, 19-48		3
147	CHAPTER 5:Fragment Screening of G Protein-Coupled Receptors. **2015**, 101-125		1
146	Chapter 8:The Discovery of the Long-acting PDE5 Inhibitor PF-489791 for the Treatment of Pulmonary Hypertension. **2010**, 166-182		2
145	Fragments: where are we now?. **2020**, 48, 271-280		16
144	Targeting the protein-protein interface pocket of Aurora-A-TPX2 complex: rational drug design and validation. *Journal of Biomolecular Structure and Dynamics*, **2021**, 39, 3882-3891	3.6	55
143	Fragment Binding to the Nsp3 Macrodomain of SARS-CoV-2 Identified Through Crystallographic Screening and Computational Docking. **2020**,		6
142	Exhaustive sampling of the fragment space associated to a molecule leading to the generation of conserved fragments. **2018**, 91, 655-667		0
141	Advancing the activity cliff concept, part II. **2014**, 3, 75		23
140	Discovery of fragment molecules that bind the human peroxiredoxin 5 active site. **2010**, 5, e9744		17
139	Hydrogen bonding penalty upon ligand binding. **2011**, 6, e19923		59
138	BcL-xL conformational changes upon fragment binding revealed by NMR. **2013**, 8, e64400		7
137	Fragment-based screening maps inhibitor interactions in the ATP-binding site of checkpoint kinase 2. **2013**, 8, e65689		19

136	The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. **2013**, 4, 1647-61		15
135	19F-NMR in target-based drug discovery. **2019**,		14
134	The role of HTS in drug discovery at the University of Michigan. **2014**, 17, 210-30		8
133	Enhancement in the Catalytic Activity of Human Salivary Aldehyde Dehydrogenase by Alliin from Garlic: Implications in Aldehyde Toxicity and Oral Health. **2019**, 20, 506-516		5
132	Applications of Quantitative Structure-Activity Relationships (QSAR) based Virtual Screening in Drug Design: A Review. **2020**, 20, 1375-1388		11
131	Adenylating enzymes in Mycobacterium tuberculosis as drug targets. **2012**, 12, 766-96		45
130	Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery. **2017**, 17, 4-15		40
129	Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. **2018**, 18, 674-699		44
128	Chemical Intuition in Drug Design and Discovery. **2019**, 19, 1679-1693		3
127	Relevance of Molecular Docking Studies in Drug Designing. **2020**, 15, 270-278		19
126	Development and Implementation of a High Throughput Screen for the Human Sperm-Specific Isoform of Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDHS). **2011**, 5, 30-41		10
125	Selective and Orally Bioavailable CHK1 Inhibitors of Some Synthesized Substituted Thieno[2,3-b]pyridine Candidates. **2015**, 11, 659-671		9
124	Structure-based discovery of potent and selective melatonin receptor agonists. **2020**, 9,		19
123	Kinetic Profiling of Ligands and Fragments Binding to GPCRs by TR-FRET. **2021**, 1-32		
122	Destabilization of Alzheimer's A□2 protofibrils with acyclovir, carmustine, curcumin, and tetracycline: insights from molecular dynamics simulations.		0
121	Drug-like Properties and Fraction Lipophilicity Index as a combined metric.. **2021**, 9, 177-190		1
120	Molecular Design in Practice: A Review of Selected Projects in a French Research Institute That Illustrates the Link between Chemical Biology and Medicinal Chemistry. *Molecules*, **2021**, 26,	4.8	
119	Discovery of Reldesemtiv, a Fast Skeletal Muscle Troponin Activator for the Treatment of Impaired Muscle Function. *Journal of Medicinal Chemistry*, **2021**, 64, 14930-14941	8.3	1

118	Promising Natural Compounds against Flavivirus Proteases: Citrus Flavonoids Hesperetin and Hesperidin. **2021**, 10,		2
117	Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs. **2021**, 60, 26663-26670		7
116	Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs.		0
115	The Process of Drug Discovery. **2006**, 147-173		
114	Chemical Libraries: Screening for Biologically Active Small Molecules. 1		
113	Chapter 1:The Chemical Genetic Approach: The Interrogation of Biological Mechanisms with Small Molecule Probes. **2010**, 1-32		
112	Chapter 9:From HTS to Market: the Discovery and Development of Maraviroc, a CCR5 Antagonist for the Treatment of HIV. **2010**, 183-214		
111	CHAPTER 9:Exploring Fragment Screening and Optimization Strategies Using Acetylcholine-Binding Protein. **2015**, 214-237		
110	CHAPTER 10:Integrating Metabolism and Toxicity Properties. **2015**, 227-246		
109	CHAPTER 8:Fragment-Based Discovery of Antibacterials. **2015**, 177-213		
108	Medicinal Chemistry Strategies to Prevent Compound Attrition. 215-228		
107	Applications of NMR Spectroscopy in FBDD. **2017**, 1-22		
106	In Silico Identification and Experimental Validation of Novel KPC-2 β-lactamase Inhibitors.		
105	Design of Favorable Compound Libraries for Biologists. **2018**, 76, 1102-1109		
104	Cheminformatic Analysis of Natural Product Fragments. **2019**, 110, 143-175		0
103	Druggability Assessment in TRAPP using Machine Learning Approaches.		
102	The Structure-Based Virtual Screening for Natural Compounds that Bind with the Activating Receptors of Natural Killer Cells.		
101	Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	7

100	Druggable Allosteric Sites in Propeller Lectins. **2021**, 61, e202109339		2
99	Allosterische, Wirkstoff-zugngliche Bindestellen in Propeller-Lektinen. **2022**, 134, e202109339		
98	Initial study on SARS-CoV-2 main protease inhibition mechanism of some potential drugs using molecular docking simulation. **2020**, 58, 665		
97	Introduction to Fragment Screening. **2007**, 49-72		1
96	Fragment-Based Screening by X-ray Crystallography. **2007**, 99-127		
95	Fragment-based Binding Efficiency Indices in Bioactive Molecular Design: A Computational Approach to BACE-1 Inhibitors. *Iranian Journal of Pharmaceutical Research*, **2013**, 12, 423-36	1.1	8
94	Novel inhibitor discovery against aromatase through virtual screening and molecular dynamic simulation: a computational approach in drug design. *EXCLI Journal*, **2013**, 12, 168-83	2.4	12
93	Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs. *Cell Journal*, **2017**, 19, 65-83	2.4	1
92	4-Chloro-orthophenylenediamine alters DNA integrity and affects cell survival: inferences from a computational, biophysical/biochemical, microscopic and cell-based study. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-12	3.6	1
91	An Inhibitor-in-Pieces Approach to DAHP Synthase Inhibition: Potent Enzyme and Bacterial Growth Inhibition. *ACS Infectious Diseases*, **2021**, 7, 3292-3302	5.5	1
90	Biotin's Lessons in Drug Design. *Journal of Medicinal Chemistry*, **2021**, 64, 16319-16327	8.3	1
89	L. Essential Oil: Odorant Binding Protein Efficiency Using Molecular Docking Approach and Studies of the Mosquito Repellent.. *Insects*, **2021**, 12,	2.8	1
88	A New Paradigm for KIM-PTP Drug Discovery: Identification of Allosteric Sites with Potential for Selective Inhibition Using Virtual Screening and LEI Analysis. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	2
87	Allosteric binding on nuclear receptors: Insights on screening of non-competitive endocrine-disrupting chemicals. *Environment International*, **2021**, 159, 107009	12.9	1
86	Inhibitory potency of Valsartan/Sacubitril drug combination: molecular docking simulations. **2021**,		
85	Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update.. *Pharmacological Research*, **2021**, 106037	10.2	22
84	Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors.. *Bioorganic and Medicinal Chemistry Letters*, **2022**, 60, 128582	2.9	0
83	Small-Molecule Lead-Finding Trends across the Roche and Genentech Research Organizations.. *Journal of Medicinal Chemistry*, **2022**,	8.3	4

82	Identification and Optimization of Novel Small-Molecule Cas9 Inhibitors by Cell-Based High-Throughput Screening.. *Journal of Medicinal Chemistry*, **2022**,	8.3	0
81	Mechanistic insight into the binding between Ferritin and Serotonin: Possible implications in neurodegenerative diseases. *Journal of Molecular Liquids*, **2022**, 351, 118618	6	0
80	Fragment-to-Lead Medicinal Chemistry Publications in 2020.. *Journal of Medicinal Chemistry*, **2021**,	8.3	7
79	Accelerating therapeutic protein design.. *Advances in Protein Chemistry and Structural Biology*, **2022** , 130, 85-118	5.3	
78	Structural basis of SARM1 activation, substrate recognition, and inhibition by small molecules.. *Molecular Cell*, **2022**,	17.6	4
77	High-Throughput Screening for Extracellular Inhibitors of the FLT3 Receptor Tyrosine Kinase Reveals Chemically Diverse and Druggable Negative Allosteric Modulators.. *ACS Chemical Biology*, **2022**,	4.9	0
76	Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches.. *Evidence-based Complementary and Alternative Medicine*, **2022**, 2022, 2832889	2.3	1
75	Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia.. *Pharmacological Research*, **2022**, 178, 106156	10.2	2
74	Discovery of Cofactor Competitive Inhibitors against the Human Methyltransferase Fibrillarin.. *Pharmaceuticals*, **2021**, 15,	5.2	
73	In silico studies on the interaction of four cytotoxic compounds with angiogenesis target protein HIF-1□and human androgen receptor and their ADMET properties. *Bulletin of the National Research Centre*, **2022**, 46,	3	1
72	Table_1.docx. **2020**,		
71	Table_1.DOCX. **2019**,		
70	Table_2.DOCX. **2019**,		
69	DataSheet_1.pdf. **2019**,		
68	DataSheet_2.zip. **2019**,		
67	Computer-aided identification of potential inhibitors against Necator americanus glutathione S-transferase 3. *Informatics in Medicine Unlocked*, **2022**, 30, 100957	5.3	
66	Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19. **2022**, 2,		0
65	Furin and COVID-19: Structure, Function and Chemoinformatic Analysis of Representative Active Site Inhibitors. **2022**, 2,		0

64	Drug-like Inhibitors of DC-SIGN Based on a Quinolone Scaffold. *ACS Medicinal Chemistry Letters*,	4.3	
63	Design of a Potent, Selective, and Brain-Penetrant Inhibitor of Wnt-Deactivating Enzyme Notum by Optimization of a Crystallographic Fragment Hit.. *Journal of Medicinal Chemistry*, **2022**,	8.3	2
62	Estrogen receptor potentially stable conformations from molecular dynamics as a structure-based pharmacophore model for mapping, screening, and identifying ligands-a new paradigm shift in pharmacophore screening.. *Journal of Biomolecular Structure and Dynamics*, **2022**, 1-10	3.6	
61	Design, Synthesis, and Biological Characterization of Inhaled p38 MAPK Inhibitors for the Treatment of Lung Inflammatory Diseases.. *Journal of Medicinal Chemistry*, **2022**,	8.3	
60	Design, Cytotoxicity and Antiproliferative Activity of 4-Amino-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylates against MFC-7 and MDA-MB-231 Breast Cancer Cell Lines. *Molecules*, **2022**, 27, 3314	4.8	
59	Targeting undruggable carbohydrate recognition sites through focused fragment library design. *Communications Chemistry*, **2022**, 5,	6.3	1
58	Homology Modeling, de Novo Design of Ligands, and Molecular Docking Identify Potential Inhibitors of Leishmania donovani 24-Sterol Methyltransferase. *Frontiers in Cellular and Infection Microbiology*, **2022**, 12,	5.9	3
57	Hearing loss drug discovery and medicinal chemistry: Current status, challenges, and opportunities. *Progress in Medicinal Chemistry*, **2022**, 1-91	7.3	1
56	An In Silico Study of the Interactions of Alkaloids from Cryptolepis sanguinolenta with Plasmodium falciparum Dihydrofolate Reductase and Dihydroorotate Dehydrogenase. *Journal of Chemistry*, **2022**, 2022, 1-26	2.3	3
55	Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization. *International Journal for Parasitology: Drugs and Drug Resistance*, **2022**,	4	0
54	Fragment-Based Drug Discovery The Importance of High Quality Molecule Libraries. *Molecular Oncology*,	7.9	2
53	More is simpler: Decomposition of ligand-binding affinity for proteins being disordered. *Protein Science*, **2022**, 31,	6.3	0
52	Riboflavin, a Potent Neuroprotective Vitamin: Focus on Flavivirus and Alphavirus Proteases. *Microorganisms*, **2022**, 10, 1331	4.9	
51	Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to Klotho. *Journal of Chemical Information and Modeling*,	6.1	0
50	Discovery of Substituted Di(pyridin-2-yl)-1,2,4-thiadiazol-5-amines as Novel Macrofilaricidal Compounds for the Treatment of Human Filarial Infections. **2022**, 65, 11388-11403		0
49	Large-Scale Ligand Perturbations of the Protein Conformational Landscape Reveal State-Specific Interaction Hotspots.		1
48	Molecular Design Method Using a Reversible Tree Representation of Chemical Compounds and Deep Reinforcement Learning.		1
47	Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders. **2022**, 183, 106362		0

46	Forces Driving a Magic Bullet to Its Target: Revisiting the Role of Thermodynamics in Drug Design, Development, and Optimization. **2022**, 12, 1438	0
45	PAC-FragmentDEL photoactivated covalent capture of DNA-encoded fragments for hit discovery.	1
44	The drug-discovery process. **2022**, 383-422	0
43	Fragment optimization and elaboration strategies the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.	0
42	Implementation of an AI-assisted fragment-generator in an open-source platform.	0
41	Development of fluorine-substituted NH2-biphenyl-diarylpyrimidines as highly potent non-nucleoside reverse transcriptase inhibitors: Boosting the safety and metabolic stability. **2022**,	0
40	Magnet for the Needle in Haystack: rystal Structure First Fragment Hits Unlock Active Chemical Matter Using Targeted Exploration of Vast Chemical Spaces.	3
39	Fragment-Based Discovery of a Novel, Brain Penetrant, Orally Active HDAC2 Inhibitor.	0
38	Rational Design and Synthesis of New Selective COX-2 Inhibitors with In Vivo PGE2-Lowering Activity by Tethering Benzenesulfonamide and 1,2,3-Triazole Pharmacophores to Some NSAIDs. **2022**, 15, 1165	0
37	From DC18 to MR07: A Metabolically Stable 4,4?-Oxybisbenzoyl Amide as a Low-Nanomolar Growth Inhibitor of P. falciparum.	0
36	Identification of a new and diverse set of Mycobacterium tuberculosis uracil-DNA glycosylase (MtUng) inhibitors using structure-based virtual screening: Experimental validation and molecular dynamics studies. **2022**, 76, 129008	0
35	In silico study of inhibitory capacity of sacubitril/valsartan toward neprilysin and angiotensin receptor. **2022**, 12, 29719-29726	0
34	Discovery of a structurally novel, potent, and once-weekly free fatty acid receptor 1 agonist for the treatment of diabetes. **2022**, 114883	0
33	Identification of Small Molecules with Improved Potency against Orthopoxviruses from Vaccinia to Smallpox.	0
32	Predicting FDA approvability of small-molecule drugs.	0
31	Development of Noncovalent Small-Molecule Keap1-Nrf2 Inhibitors by Fragment-Based Drug Discovery.	1
30	Computational study of potential inhibitors for fat mass and obesity-associated protein from seaweed and plant compounds. 10, e14256	0
29	Recent trends in fragment-based anticancer drug design strategies against different targets: A mini-review. **2022**, 206, 115301	0

28	From dopamine 4 to sigma 1: Synthesis, SAR and biological characterization of a piperidine scaffold of 1 modulators. **2022**, 244, 114840	0
27	Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.	0
26	Novel rhodanine based inhibitors of aldose reductase of non-acidic nature with p-hydroxybenzylidene functional group. **2022**, 114922	0
25	Reactivity of Covalent Fragments and Their Role in Fragment Based Drug Discovery. **2022**, 15, 1366	2
24	The discovery of (1R, 3R)-1-(3-chloro-5-fluorophenyl)-3-(hydroxymethyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile, a potent and selective agonist of human transient receptor potential cation channel subfamily m member 5 (TRPM5) and evaluation of as a potential gastrointestinal prokinetic agent. **2022**, 76, 117084	0
23	Properties of FDA-approved Small Molecule Protein Kinase Inhibitors: A 2023 Update. **2022**, 106552	6
22	Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design. **2023**, 246, 114945	0
21	Natural Compounds as Non-Nucleoside Inhibitors of Zika Virus Polymerase through Integration of In Silico and In Vitro Approaches. **2022**, 15, 1493	0
20	The Identification of Potent, Selective, and Brain Penetrant PI5P4K Inhibitors as In Vivo-Ready Tool Molecules.	2
19	New Derivatives of the Multi-Stage Active Malaria Box Compound MMV030666 and Their Antiplasmodial Potencies. **2022**, 15, 1503	0
18	The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy. **2022**, 27, 9041	0
17	Synthesis, Cytotoxic Evaluation, and Structure-Activity Relationship of Substituted Quinazolinones as Cyclin-Dependent Kinase 9 Inhibitors. **2023**, 28, 120	0
16	Integration of Synthetic Organic Chemistry and <i>in silico</i> Drug Discovery - Lead Discovery of Renin Inhibitors and <i>O</i>-GlcNAcase Inhibitors. **2023**, 81, 25-34	0
15	Fragment-to-Lead Medicinal Chemistry Publications in 2021.	0
14	Structure-based Drug Discovery and Advances in Protein Receptor Crystallography. **2017**, 45-72	0
13	Exploration of Novel Scaffolds Targeting Cytochrome b of Pyricularia oryzae. **2023**, 24, 2705	0
12	Methyl and Fluorine Effects in Novel Orally Bioavailable Keap1 Nrf2 PPI Inhibitor.	0
11	Propitious Indazole Compounds as ketoacyl-ACP Synthase Inhibitors and Mechanisms Unfolded for TB Cure: Integrated Rational Design and MD Simulations. **2023**, 8,	0

10	Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference**. **2023**, 62,	0
9	Chemical Validation of Mycobacterium tuberculosis Phosphopantetheine Adenylyltransferase Using Fragment Linking and CRISPR Interference**. **2023**, 135,	0
8	Dockey: a modern integrated tool for large-scale molecular docking and virtual screening. **2023**, 24,	1
7	E3 Ligases Meet Their Match: Fragment-Based Approaches to Discover New E3 Ligands and to Unravel E3 Biology. **2023**, 66, 3173-3194	0
6	Antitarget, Anti-SARS-CoV-2 Leads, Drugs, and the Drug Discovery Genetics Alliance Perspective. **2023**, 66, 3664-3702	0
5	Key Biochemical Aspects of Drug-Target Interactions. **2023**, 65-69	0
4	Docking and Molecular Dynamics Identify Leads against 5 Alpha Reductase 2 for Benign Prostate Hyperplasia Treatment. **2023**, 2023, 1-20	0
3	Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP-TEAD Protein-Protein Interaction Inhibitors.	0
2	Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach. **2023**, 28, 3103	0
1	Rule of five violations among the FDA-approved small molecule protein kinase inhibitors. **2023**, 106774	0